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1. Introduction 
Muscular dystrophies are inherited disorders in which muscle fibers are unusually susceptible 
to damage, leading to progressive loss of muscle structure and function. Some types of 
muscular dystrophy affect heart muscles, other involuntary muscles and other organs. The 
most common form of muscular dystrophy, Duchenne Muscular Dystrophy (DMD), is due to 
genetic deficiency of the protein dystrophin (Monaco et al., 1985). This protein is one of several 
partners that interact to link intracellular cytoskeleton to extracellular matrix (ECM) hence 
consolidating the scaffold necessary for maintaining structural integrity of skeletal muscle 
fibers. Dystrophin deficiency destabilizes muscle fibers, which become less resistant to 
contractions leading to muscle fiber necrosis and subsequent regeneration.  
Skeletal muscle repair, maintenance and regeneration are mediated by muscle-specific stem 
cells: the satellite cells (Mauro, 1961), located underneath basal lamina of muscle fibers. In 
DMD muscles, fat and connective tissue often replace muscle fibers in the late stages of 
muscular dystrophy, indicating that muscle regeneration does not keep up with fiber loss. 
Defective muscle regeneration could be due to exhaustion of proliferative capacity of 
satellite cells (Blau et al., 1983; Webster & Blau, 1990) or to environmental factors that are not 
conducive to their function. The healing process usually includes sequential and 
overlapping events of muscle fiber degeneration, inflammatory reaction, regeneration and 
remodeling of ECM components that require tightly regulated orchestration of the 
interactive cross-talk that conditions the outcome of the regenerative process. Uncontrolled 
wound-healing, in response to chronic injury and inflammation, results in tissue fibrosis and 
scarring which impacts on the efficiency of muscle regeneration, hence contributing to the 
degradation of muscle function. 
At present, we still have no cure for any form of muscular dystrophy, but medications and 
therapy can slow the course of the disease to allow people with muscular dystrophy to 
remain mobile for as long as possible. Nevertheless, experimental therapeutic strategies 
have been initiated in light of basic and technical advances of skeletal muscle biology and 
pathophysiology. The description of the muscle regeneration process and the identification 
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of the cells responsible for myofiber regeneration led to stem cell therapy being considered 
as a potential strategy to alleviate muscle deficiency in DMD patients. Alternatively, the 
identification of gene defects and the sophistication of molecular biology technologies have 
opened perspectives for gene therapy, either by providing the deficient gene, or by restoring 
gene function. Other strategies combining both approaches have been considered and imply 
the correction of patients’ own stem cells before grafting them into the diseased muscles. 
These promising strategies have been challenged in animal models of muscular dystrophies 
and although they achieved a certain success, they also identified a number of limitations. 
Moreover, the failure of myogenic cell grafting to improve muscle function and to restore 
dystrophin expression in clinical trials of DMD patients, underscored the need to improve 
the efficiency of cell therapy. Cell environment, which comprises ECM and extracellular 
matrix deposited factors such as growth factors, cytokines and chemokines, regulate diverse 
cellular functions. These molecules are metabolized by Matrix MetalloProteinases (MMPs) 
that play a central role as regulators of tissue microenvironment. In normal situations, 
precise spatiotemporal repertoires of MMPs balanced by inhibitors, among which are the 
four Tissue Inhibitors of MatrixmetalloProteinases (TIMPs), regulate extracellular signaling 
networks and maintain tissue homeostasis. On the contrary, increased MMPs expression or 
activity has been demonstrated in various disease situations including, practically every 
known inflammatory disease (Manicone & McGuire, 2008). Such disruption of the dynamic 
equilibrium between MMPs and TIMPs may affect diverse cellular functions including cell 
proliferation, migration, adhesion and apoptosis (Holmbeck et al., 2005; Hulboy et al., 1997; 
Vu & Werb, 2000). In DMD, for example, inflammation and fibrosis are major hurdles in the 
path of therapeutic strategies (Wells et al., 2002) and their resolution is expected to 
positively impact on the efficiency of any form of therapy, but more specifically, on the 
efficiency of cell therapy. Indeed, myogenic stem cells have limited migratory capacity, 
which is further aggravated by excessive proliferation of connective tissue. Therefore, 
improving the efficiency of cell therapy could be achieved either by myogenic cells better 
able to digest accumulated ECM components or, alternatively, by other types of stem cells 
that can be recruited from a resident or circulating pool and are capable of migrating 
through one or several tissue barriers to home into skeletal muscles. In this chapter, we 
consider the use of stem cell therapy to treat muscular dystrophies. By going through the 
different cell types that have been used, we will try to define the best cell type to use, how to 
handle and expand these cells before transplantation and the best route of delivery. 
Moreover, the possibility of using genetically-modified autologous stem cells for 
transplantation will be presented. This would only be possible if the stem cell had not been 
deleteriously affected by the dystrophic environment. Finally, we will consider the host 
environment as a modulator of cell behaviour and the dual role MMPs play in the control of 
this environment and their impact on transplanted cells migration, differentiation and self-
renewal. 
2. Potential therapies for duchenne muscular dystrophy 
Muscular dystrophies are a heterogeneous group of inherited neuromuscular disorders, 
including X-linked recessive as in DMD, autosomal recessive as in limb–girdle muscular 
dystophy type 2, or autosomal dominant as in facioscapulohumeral muscular dystophy, 
myotonic dystrophy, and limb–girdle muscular dystophy type 1 (Emery, 2002). In the last 
two decades, different types of dystrophies have been genetically characterized. The most 
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frequent and most severe form, DMD, is a progressive, incurable X-linked recessive disorder 
that affects 1 in 3500 newborn boys and leads to death in the second or third decade of life 
(Bushby et al., 2010). DMD patients lack the protein dystrophin while in-frame mutations of 
the same gene led to expression of a partially functional protein, resulting in the milder 
Becker muscular dystrophies (BMD). As a result of the absence of dystrophin, muscle fibers 
of DMD patients undergo necrosis followed by regeneration which, in the long run, fails to 
keep up with the recurrent cycles of degeneration-regeneration and muscle fibers are lost 
and replaced by fibro-fatty tissue. Interruption of these cycles can be achieved by dystrophin 
restoration to the muscle fiber membrane (Meng et al., 2011a). Several strategies can now be 
used to restore dystrophin to the muscle fibers of affected patients. They include virally-
mediated gene therapy, read-through of stop codons, up-regulation of compensatory genes, 
or skipping of mutated dystrophin exons to give rise to a shorter, but still functional 
dystrophin protein. However, all of these have possible drawbacks (reviewed (Goyenvalle & 
Davies, 2011; Guglieri & Bushby, 2010; Hoffman et al., 2011; Sugita & Takeda, 2010)). Either 
gene therapy, or application of antisense oligonucleotides to skip mutated dystrophin exons, 
requires that the patient has sufficient muscle fibers remaining for treatment. In addition, 
exon skipping is mutation-dependent and not all patients have mutations amenable to this 
approach.  
3. Stem cell therapy for the treatment of DMD 
The concept of a cell-based therapy to alleviate loss of muscle structure and function in 
muscular dystrophy originated with the observation of the intrinsic ability of myogenic 
stem cells to fuse either with each other to form multinucleated myofibers, or with necrotic 
muscle fibers to form mosaic fibers. In theory, functional correction could be achieved in 
DMD by the generation of either hybrid muscle fibers where the donor nuclei provide the 
missing gene product and/or the regeneration of normal myofibers from the fusion of 
normal donor cells to replace lost muscle fibers. Cell therapy was the first biologically based 
approach applied for the treatment of DMD and required the use of animal models to 
explore the beneficial effects of this therapy. The ability of cultured myogenic cells to 
regenerate new muscle fibers, that reconstitute the same architectural organization of the 
original muscle and induce functional recovery,  has been validated using an experimental 
model of irreversible injury to adult rodent muscle associating auto-transplantation of 
skeletal muscle to X-irradiation (Alameddine et al., 1989; Alameddine et al., 1991; Alameddine 
et al., 1994).  
3.1 Stem cells 
Stem cells are defined as cells that can both self-renew and give rise to more differentiated 
cell type, whereas precursor cells do not have the ability to self-renew. Both cell types 
present a great advantage for the treatment of muscular dystrophies as they could repair 
segmental necrosis and also give rise to regenerated muscle fibers to replace those that are 
lost as a consequence of the dystrophy. They could therefore be effective at later stages of 
the dystrophy, when muscle fibers have already been lost. Donor cells derived from a 
normal individual will automatically express dystrophin when they differentiate into a 
muscle fiber, but the quantity and distribution of dystrophin within the fiber will depend on 
the number of donor myonuclei and the size of segments of the fiber to which they 
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contribute. However, the recipient and donor will need to be HLA-matched, so that stem 
cells from one normal donor could not be used to treat all patients.  
Although many different stem or precursor cells have been shown to contribute to muscle 
regeneration in animal models, many of these give rise to only limited amount of muscle, for 
example haematopoietic stem cells (Ferrari et al., 1998) and mesenchymal stem cells (Chan 
et al., 2006; Meng et al., 2010). Satellite cells are the archetypal skeletal muscle stem cell, but 
they are by definition quiescent cells underneath the basal lamina of muscle fibers and it 
would be impossible to obtain enough of them for therapeutic application. However, the 
progeny of satellite cells, muscle precursor cells or myoblasts, could be prepared in 
sufficient quantity for transplantation. In this review, therefore, we will focus on cells that 
can be expanded in culture and that have been shown to contribute to muscle regeneration- 
myoblasts, cells derived from blood-vessel associated pericytes (termed mesoangioblasts) 
and skeletal muscle-derived AC133+ cells. There are several recent reviews on stem cells to 
treat muscular dystrophies, which cover most of the cell types that have been studied (Meng 
et al., 2011a; Negroni et al., 2011; Palmieri et al., 2010; Skuk & Tremblay, 2011; Tedesco et al., 
2010). 
3.2 Models and markers 
To investigate the potential contribution of a particular cell type to muscle regeneration, the 
standard experiment is to graft the cells into an animal model of DMD and measure their 
contribution to skeletal muscle fibers, which may be quantified by either counting the 
number of dystrophin-positive fibers, or measuring the amount of dystrophin on western 
blot. Several animal models of DMD exist but the most widely-used is the dystrophin-
deficient mdx mouse (Bulfield et al., 1984) used in 1,940 pubmed publications, as of 21 July 
2011. Other models of DMD include the golden retriever muscular dystrophy (GRMD also 
known as Canine X-linked Muscular Dystrophy CXMD) dog and zebrafish (reviewed 
(Banks & Chamberlain, 2008; Collins & Morgan, 2003)). Mouse and dog models have been 
used to investigate different potential therapies for DMD, including precursor/stem cell 
transplantation (Nakamura & Takeda, 2011). However, when grafting cells from one donor 
to another, the host must either be immunodeficient or immunosuppressed. Therefore, mdx 
mice with different types of immunodeficiency have been used as hosts in cell 
transplantation experiments, including mdx nu/nu (Boldrin et al., 2009; Collins et al., 2005; 
Partridge et al., 1989), SCID mdx (Benchaouir et al., 2007; Dellavalle et al., 2007; Torrente et 
al., 2004), Rag-/- mdx (Gerard et al., 2011), or mdx mice immunosuppressed with FK506 
(Kinoshita et al., 1994b), but to what extent these different hosts are comparable, being on 
different genetic backgrounds and having different mechanisms and degrees of 
immunodeficiency, has not been ascertained (reviewed (Meng et al., 2011b)). Immunodeficient 
mice are more convenient to work with than mice that have to be immunosuppressed and 
seem to permit greater donor-myoblast-derived muscle regeneration (Partridge et al., 1989). 
However, it is important to consider the effect of the immunological system on donor-
derived muscle regeneration, as DMD patients will not be immunodeficient. Non-
dystrophic mice or monkeys, whose muscles have been injured to mimic the degeneration 
and regeneration that occurs in dystrophic muscles, have also been used as recipients to test 
cell transplantation (Cooper et al., 2001; Morgan et al., 2002; Sacco et al., 2008; Skuk et al., 
1999), as have mice that model different types of dystrophy, e.g. sarcoglycan (Sampaolesi et 
al., 2003) and dysferlin-deficient mice (Diaz-Manera et al., 2010). 
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A major consideration when using both dystrophic and non-dystrophic animal models to 
test stem cells is that the host muscle usually has to be injured in some way to enhance 
donor cell engraftment. This is surprising, as the muscle fiber degeneration and regeneration 
that is already occurring in dystrophic muscle would be thought to be sufficient to promote 
donor stem cells to contribute to muscle regeneration. However, muscle fiber necrosis is 
often focal and only cells located nearby contribute to regeneration (Yokota et al., 2006). 
Therefore, if the transplanted stem cell is located a distance away, it may not either receive 
the correct signals, or be able to migrate to the damaged fibers. As many of these injury 
regimes are very severe, for example, cryoinjury (Brimah et al., 2004; Irintchev et al., 1997; 
Negroni et al., 2009) or use of snake venoms (Lefaucheur & Sebille, 1995; Silva-Barbosa et al., 
2005) to induce degeneration and regeneration in host muscles, they could not be used in 
patients. Even in dystrophin-deficient mdx nu/nu host mice, satellite cells contribute little, if 
any, to muscle regeneration (Boldrin et al., 2009; Collins et al., 2005) although myoblasts 
contribute to muscle regeneration to a greater extent ( Morgan et al., 2002; Partridge et al., 
1989). This poor contribution of donor cells to muscle regeneration is likely to be due to the 
fact that mdx mouse muscles, in contrast to those of DMD patients, regenerate very well. We 
therefore blocked muscle regeneration in mdx muscles by applying local high doses of 
radiation, to obtain a model more similar to DMD, in which the muscle degenerates and 
atrophies but does not regenerate (Morgan et al., 1990; Pagel & Partridge, 1999; Wakeford et 
al., 1991). If host muscle is irradiated with 18 Gy before donor cell grafting, satellite cell and 
myoblast contribution to muscle regeneration is significantly augmented (Boldrin et al., 
2009; Collins et al., 2005; Morgan et al., 2002). This may be due to prevention of competition 
from local host stem or satellite cells, as irradiated mdx muscles do not regenerate (Pagel & 
Partridge, 1999; Wakeford et al., 1991) unless a severe injury, e.g. injection of snake venom 
notexin, is imposed on them, which evokes rare radiation-resistant stem cells to regenerate 
(Gross & Morgan, 1999; Heslop et al., 2000). Other models that could be used to test whether 
a wholly or partially emptied satellite cell niche is necessary for efficient donor muscle stem 
cell engraftment include Pax7 knockout mice (Seale et al., 2000) that lack satellite cells, or the 
mdx mouse that also lacks telomerase (mTR) activity and therefore shows a reduction in the 
regenerative capacity of myogenic stem cells (Sacco et al., 2010). 
Another important consideration is the marker(s) to be used to assess the contribution of 
donor cells to regenerated muscle fibers and/or satellite cells (reviewed (Meng et al., 
2011a)). As the aim is to produce dystrophin in host muscle fibers, it is sensible to quantify 
dystrophin restoration in the host muscles (Partridge et al., 1989). Because “revertant” fibers 
that spontaneously express dystrophin are present in animal models of DMD (Hoffman et 
al., 1990) and in DMD patients (Arechavala-Gomeza et al., 2010) and because clusters of 
revertant fibers increase in number with time (Hoffman et al., 1990; Yokota et al., 2006), 
revertant fibers must be controlled for, particularly if dystrophin is being used alone as a 
marker of donor-derived muscle fibers and especially in time course studies. If grafting 
human cells into mouse, a human-specific dystrophin antibody (e.g. Novocastra Dys3 
(Brimah et al., 2004)) may be used, that will not identify mouse revertant fibers. Because of 
the existence of revertant fibers, many groups use a second marker of either muscle fibers or 
cells of donor origin, e.g. by using donor cells from genetically-modified mice, e.g. myosin 3f 
nLacZ-E, that is expressed in myonuclei of donor origin, Myf5 nLacZ/+ that is expressed in 
satellite cells of donor origin (Collins et al., 2005), or ubiquitously (Morgan et al., 2002) or 
muscle-specifically (Kinoshita et al., 1994a) expressed -gal or GFP. Donor cells may 
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alternatively be marked in culture with constructs expressing a marker protein (Blaveri et 
al., 1999; Cousins et al., 2004; Diaz-Manera et al., 2010; Morgan et al., 2002). However, 
caution should be used in interpreting results, as GFP is notoriously difficult to use in 
skeletal muscle (Jackson et al., 2004), some markers spread further along a mosaic muscle 
fiber than others (Blaveri et al., 1999) and others are switched off in vivo (Boldrin et al.,2009). 
3.3 Contribution of locally-delivered donor stem cells to muscle regeneration. 
A large body of evidence can be found in the literature to illustrate the contribution of 
myoblasts to skeletal muscle regeneration, although the number of donor-derived muscle 
fibers is limited (Figure 1). However, the host muscle environment that permits regeneration 
from myoblasts of mouse and human origin appears to be different, although a comparative 
experiment to establish this point has not been performed: human myoblasts form more 
muscle within host muscles that have been cryoinjured prior to grafting (Brimah et al., 
2004), whereas mouse myoblasts form significantly more muscle in irradiated host muscles 
(Boldrin and Morgan, manuscript in preparation). 
Different muscle injury models used for intra-muscular grafting of putative muscle stem 
cells may also give rise to discrepancies between groups. Some groups have grafted cells 
into muscles of non-dystrophic mice that had been cryo-injured immediately prior to 
grafting (Brimah et al., 2004; Cooper et al., 2001; Ehrhardt et al., 2007), but others grafted 
cells into muscles of mdx SCID mice that had been injected 48 hours previously with 
cardiotoxin, (Dellavalle et al., 2007) or into cryo–injured muscles of immunodeficient Rag2-/-
gamma chain-non-dystrophic mice (Pisani et al., 2010). Vauchez et al. grafted into muscles 
of non-dystrophic SCID mice, injuring the muscles prior to grafting by a combination of 
irradiation and notexin (Vauchez et al., 2009); Zheng et al. grafted cells into muscles of SCID 
mice that had been injured by cardiotoxin one day previously (Zheng et al., 2007). How 
these different injury regimes mimic the dystrophic muscle environment and to what extent 
the local environment, genetic background and immunological status of the host mouse 
affect muscle stem cell behavior are important to determine, for the identification of robust 
methodologies which could reliably be used for therapeutic trials in muscular dystrophies. 
Interestingly, although they contributed to much muscle regeneration after intra-arterial 
injection, pericytes only gave rise to very small numbers of muscle fibers after intra-
muscular transplantation: CD56+/ALP- cells (satellite-cell derived myoblasts) gave rise to 
more muscle than CD56+/ALP+ cells (pericytes), but CD56-/ALP- cells, taken to be 
fibroblasts, made very few donor muscle fibers (Dellavalle et al., 2007). Meng et al. also 
found that both CD56+ and CD56- skeletal muscle-derived cells contributed to muscle 
regeneration, CD56+ cells making significantly more muscle than either CD56-, or non-
fractionated cells after intra-muscular transplantation. CD56+ cells contributed 
predominantly to nuclei inside the basal lamina of muscle fibers, i.e. within muscle fibers 
and/or satellite cells. But CD56- or non-sorted cells contributed to significantly more nuclei 
outside the basal lamina, confirming that there were more non-myogenic cells within CD56- 
cell population (Meng et al., 2011b). Zheng et al showed that human skeletal muscle-derived 
CD56+ cells that also expressed CD34 and CD144 (myoendothelial cells) contributed to more 
muscle regeneration than did CD56+/CD34-/CD144- cells (myoblasts) (Zheng et al., 2007) in 
contrast to the findings of Meng suggesting that pericytes, rather than endothelial cells, are 
the major CD56- contributor to muscle regeneration (Meng et al., 2011b)  
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Fig. 1. 7 µm transverse cryosection of mdx nu/nu host tibialis anterior muscle, that had been 
cryoinjured and grafted with 5 x 105 human skeletal muscle-derived stem cells 4 weeks 
previously. Stained with antibodies to human spectrin and human specific lamin a/c, that 
recognise muscle fibers and nuclei of human origin respectively. Counterstained with DAPI. 
Bar= 50 µm. (Courtesy of Dr Jinhong Meng). 
3.4 Contribution of systemically-delivered donor stem cells to muscle regeneration 
The contribution of blood vessel-derived cells (both from skeletal muscle and embryonic 
dorsal aorta) to skeletal muscle regeneration in vivo after their systemic delivery has been 
demonstrated in several publications (Dellavalle et al., 2007; Sampaolesi et al., 2003; 
Sampaolesi et al., 2006)(reviewed (Sancricca et al., 2010)), however these promising findings 
could not be replicated by others (Meng et al., 2011b). For long-term efficacy, it would be 
useful to know whether a grafted pericyte self-renews to give more functional pericytes and 
if so, what contribution these have to further muscle regeneration. Another stem cell that is 
promising for systemic delivery to skeletal muscle is the AC133+ cell, derived from either 
blood (Torrente et al., 2004), or skeletal muscle (Benchaouir et al., 2007).  
3.5 Death and proliferation of grafted cells 
Donor myoblasts die on intra-muscular grafting (Beauchamp et al., 1999; Skuk et al., 2002; 
Smythe et al., 2000) possibly as a result of one or a combination of various factors: cell 
dissociation, trophic factor withdrawal, oxidative stress, excito-toxicity, hypoxia and, 
possibly, anoikis (reviewed (Gerard et al., 2011; Skuk & Tremblay, 2011)) and much effort 
has been expended to prevent this death (reviewed (Skuk & Tremblay, 2011)). Recent 
experiments have indicated that the number and density of cells transplanted into one site 
intra-muscularly may also be critical factors influencing their survival and proliferation 
(Pellegrini & Beilharz, 2011) and that more cells may not give rise to more muscle fibers of 
donor origin (Pellegrini & Beilharz, 2011; Praud et al., 2003; Rando & Blau, 1994), possibly 
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because cells in the centre of dense pellets undergo more apoptosis. But another theory is 
that the cells that die are irrelevant, as those that survive proliferate extensively under 
appropriate environmental conditions, to reconstitute the host muscle (Beauchamp et al., 
1999). It is however unclear whether other types of muscle stem cell undergo death after 
transplantation, or if they proliferate within the grafted muscles. 
3.6 Signals inducing muscle stem cells to contribute to muscle regeneration 
Intra-arterial injection of mesoangioblasts has shown that only a very small percentage reach 
downstream skeletal muscles, most being trapped in the filter organs. To enable cells to exit 
blood vessels, the vessels must express the appropriate adhesion molecules for that cell type. 
Molecules that have been shown to be important for mesangioblast extravasation into skeletal 
muscle include HMGB1, SDF-1 and TNF- (Palumbo et al., 2004). Expression of the adhesion 
molecules L-selectin and alpha 4 integrin on mesoangioblasts improved their migration into 
skeletal muscle (Galvez et al., 2006). Pre-treatment with nitric oxide was shown to augment the 
positive effects of TNF-, TGF- and VEGF on mesangioblast migration (Sciorati et al., 2006).  
Once the donor stem cells have entered the muscles, they must migrate to sites of injury, 
proliferate to give a pool of muscle precursor cells and then differentiate to form muscle 
fibers, either by fusing with each other or by repairing necrotic segments of dystrophic 
fibers. This will require them to respond to a new series of signals, which might be more 
appropriate for satellite cells than for stem cells.  
In order to have long term benefit, the donor stem cells muscle repopulate a stem cell niche 
within the muscle and must retain the properties of a functional muscle stem cell within this 
niche. It is not clear if pericytes within their niche contribute to muscle regeneration, so the 
best niche to occupy would be the satellite cell niche. However, efficient repopulation of any 
niche, for example, the satellite cell niche, would only be possible if it were emptied as a 
consequence of the dystrophy and if the niche environment remains permissive for donor-
derived stem cell function. As satellite cell of donor origin are most commonly found on 
fibers containing myonuclei of donor origin, they may not be called upon to regenerate, as 
the fiber on which they are situated will already have been strengthened by the new 
dystrophin and may not undergo further necrosis, at least at the sites where dystrophin is 
expressed. A means of activating these cells and drawing them towards more distant areas 
of injury is therefore required to enable them to respond to future muscle fiber necrosis 
elsewhere within the muscle.  
3.7 Autologous cell transplantation 
An attractive proposition for treating muscular dystrophies is to use genetically-corrected 
autologous stem cells. The use of autologous stem cells should circumvent the need for 
immunosuppression, although tissue culture components or expression of novel protein 
isotypes in vivo may evoke an immunological reaction. But, if the stem cells are skeletal-
muscle derived, their function may be impaired by either the primary genetic defect, or 
secondary environmental consequences of the primary defect.  
In some muscular dystrophies, the gene responsible is not expressed in satellite cells 
(reviewed (Morgan & Zammit, 2010)); for example, dystrophin is not expressed in satellite 
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cells (or other types of muscle stem cell), so satellite cells in DMD muscles would therefore 
be expected to have normal function. However, the satellite cells may have undergone many 
divisions in their previous attempts to repair the dystrophic fibers and could therefore be 
close to senescence (Decary et al., 1996; Decary et al., 1997; Webster & Blau, 1990). They 
would consequently be of little use for autologous therapy, as they would undergo 
insufficient divisions in vitro to be genetically modified and then to proliferate following 
transplantation. But although human myoblasts are exhausted in DMD (Decary et al., 1996; 
Decary et al., 1997; Webster & Blau, 1990), mdx satellite cells do not appear to suffer the same 
consequence of dystrophin deficiency (Bockhold et al., 1998). Recent evidence has indicated 
that mdx satellite cells are highly functional following transplantation into irradiated mdx 
nu/nu muscles (Boldrin and Morgan, unpublished observations). So although satellite cells 
may not be lost in DMD (reviewed (Boldrin et al., 2010)), their function is compromised, 
which may be due to telomere shortening leading to reduced proliferative capacity, or a 
change in the timing or extent of differentiation. However, caution must be taken when 
comparing mdx and DMD cells, as there are differences in telomere biology between mice 
and humans: inbred mouse strains have extremely long telomeres (20–150 kilobases) 
compared with humans (up to 15 kilobases) (Bekaert et al., 2005) and telomerase activity is 
lower in human compared to mouse cells (reviewed (Mather et al., 2011)). 
It is unclear whether skeletal muscle-resident cells other than satellite cells contribute to 
muscle regeneration in muscular dystrophies, or even to maintenance and repair of normal 
muscle. If they had not actively contributed to the cycles of degeneration and regeneration 
that occur in DMD, they would be capable of many more divisions than the satellite-cell 
derived myoblasts and therefore be a more attractive candidate for autologous therapy. 
However, if they do not contribute to muscle regeneration in DMD, why do they not do so? 
And why would they be effective after transplantation, if they are not functional in situ? 
Possibly they are not recruited to muscle fiber maintenance and regeneration when they are 
in their natural niche in vivo, but do so after they encounter the site of muscle damage after 
either intra-muscular or systemic injection.  
An ideal autologous stem cell would be derived non-invasively, e.g. from the peripheral 
blood, or a skin biopsy. However, to date there is only one report of blood-derived stem 
cells that make reasonable amounts of muscle after their systemic delivery (Torrente et al., 
2004). 
3.7.1 Genetic modification of autologous cells. 
Genetic correction of autologous stem cells has been successfully used as a therapeutic 
option in other conditions and encouraging preclinical results have also been recently 
obtained in animal models of DMD (Meregalli et al., 2008). However key questions that 
need to be resolved before this approach could be used in DMD include the optimal vector 
configuration and the safety profile of the gene delivery methodology. Lentiviral vectors 
efficiently infect quiescent cells, including stem cells (S. Li et al., 2005) and give long-term, 
heritable, gene expression because they integrate into the host genome. Drawbacks with 
lentiviral vectors include possible gene silencing, or mutagenesis (Wilson & Cichutek, 2009), 
due to the site at which the virus inserts into the host genome. Although lentiviruses 
integrate preferentially into active transcription sites (Ciuffi, 2008) the development of third 
generation lentiviruses with advanced SIN design (Bokhoven et al. 2009), physiological 
www.intechopen.com
 
Muscular Dystrophy 
 
418 
promoters and cell-specific envelope proteins (Rahim et al., 2009) and enhancer-less 
regulatory elements, e.g. the ubiquitously acting chromatin opening element (UCOE) 
(Montini et al., 2006; Zhang et al., 2007) should circumvent these problems.  
A lentiviral vector has been used to insert a 6.8 kb dystrophin mini gene (S. Li et al., 2005), to 
give rise to a shorter dystrophin protein in regenerated muscle fibers. While these 
engineered mini-dystrophins appear to retain most of the functional properties of full-length 
dystrophin, they nevertheless miss important domains, such as the nitric oxide synthase 
anchoring domain (Lai et al., 2009). Considering the cloning capacity of lentiviral vectors 
(up to 10kb (M. Kumar et al., 2001)), it should be possible to further optimise a vector so that 
it accommodates most of the functionally relevant coding region of dystrophin. An optimal 
dystrophin construct in a lentiviral vector could be used to treat patients with different 
mutations, in contrast to the U7 constructs, which, although they can be placed in a 
lentiviral vector and induce dystrophin expression in stem cells in vitro and following their 
transplantation in vivo (Quenneville et al., 2007), are mutation-specific.  
4. Matrix Metalloproteinases: modulators of microenvironment and cell 
function in skeletal muscles 
The Matrix Metalloproteinases (MMPs) are a large group of zinc-dependent extracellular 
endopeptidase proteinases within the Metzincin superfamily of protease that also includes a 
disintegrin and metalloproteinases (ADAM) and ADAM with thrombospondin motifs 
(ADAMTS). MMPs family comprises 23 members in humans that share common modular 
domains and form 5 main sub-groups based on their structure and substrate: collagenases, 
gelatinases, matrilysins, stromelysins and membrane-type (Figure 2). With the exception of 
membrane bound MMPs, the other members of the group are secreted in the extracellular 
space where they are present in latent forms and become activated by other proteases or in 
response to signaling events. Their activity is regulated at the transcriptional and post-
transcriptional levels as well as by their physiological inhibitors, Tissue Inhibitors of Matrix 
Metalloproteinases (TIMPs). Collectively, they are able to degrade all components of the 
ECM. Initially confined to the degradation of ECM, their function has progressively evolved 
and they are now regarded as major regulators of tissue environment and cell functions 
(Murphy, 2010; Rodriguez et al., 2010). They modulate cell proliferation, adhesion, 
migration and signaling (Fanjul-Fernandez et al., 2010). 
4.1 Matrix Metalloproteinases in remodeling muscles 
The adult skeletal muscle is a very stable tissue yet it is endowed with a high capacity to 
adapt to modification of functional demands, trauma or disease. In normal situations, the 
dynamic equilibrium between MMPs and TIMPs maintains homeostasis of ECM that 
provides a dynamic support and stores a number of growth factors that are liberated during 
ECM remodeling. In response to remodeling situations, dysregulation of this balance occurs 
in favor of MMPs, to allow necessary hydrolysis of ECM which results in the liberation of 
neo-epitopes from basement membrane components, as well as various growth factors and 
signaling molecules that modulate cell response to environmental modifications. Such 
imbalance may be temporary and the equilibrium is restored upon the disappearance of 
remodeling stimuli.  
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Fig. 2. Structural domains and nomenclature of the matrix metalloproteinases, A: Schematic 
representation of modular domains composing MMPs which are translated as inactive 
zymogens with an amino terminal signal peptide (SP), a pro-domain which folds over the zinc 
ion, in the catalytic site, to maintain latency (Pro), a catalytic domain that carries zinc at the 
active site, a hemopexin that confers the specificity to and interaction with the substrates or 
inhibitors (TIMPs) and presents the substrate to the catalytic site via a highly flexible hinge 
domain. Membrane-type (MT-) MMPs are anchored to the membrane either with a 
hydrophobic domain and a short cytoplasmic tail (Type I transmembrane protein) or with a 
glycosyl-phosphatidyl-inositol (GPI) domain. Gelatinases A and B also contain three collagen-
binding fibronectin type II repeats within the catalytic domain and MMP-9 has an additional 
Serine-Threonine and proline rich O-Glycosylated domain. Some MMP have a furin-like motif 
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between the pro- and catalytic domains that allow their activation before they are secreted or 
localize to the membrane. MMP- 22 has a cysteine/proline rich, interleukin-1R domain and an 
Immunoglobulin–like domain. Compiled from (Bourboulia & Stetler-Stevenson, 2010; Fanjul-
Fernandez et al., 2010; Rosenberg, 2009; Sternlicht & Werb, 2001). 
In skeletal muscles, normal muscle development, limb immobilisation, electrical stimulation 
and muscle injury are all remodeling situations characterized by MMPs/TIMPs 
dysregulation. However, the nature of MMPs that is upregulated and the time frame of this 
upregulation depend, a great deal, on the model used. Immobilization or unloading, that 
result in muscle fiber atrophy, induce upregulation of both MMP-2 and MMP-9 and 
downregulation of TIMPs (Berthon et al., 2007; Giannelli et al., 2005; Reznick et al., 2003; 
Stevenson et al., 2003; Wittwer et al., 2002) (Berthon et al., 2007; Giannelli et al., 2005; 
Reznick et al., 2003; Stevenson et al., 2003; Wittwer et al., 2002 ) but only MMP-2 is active 
(Liu et al., 2010). Whereas a single bout of degeneration-regeneration, induced by 
experimental injury to the muscle, also results in upregulation of these two proteases but the 
time frame and intensity differ according to the type/extent of injury (Ferre et al., 2007; 
Frisdal et al., 2000; Kherif et al., 1999). In a cardiotoxin injury model that induced massive 
myofiber necrosis, gelatinase activity progressively increased and peaked at day 7, when 
muscle fiber formation was the most active. It then returned to normal at later stages. This 
increase was due to simultaneous and consecutive steps of gelatinases regulation- both 
expression and activation. Within hours after tissue injury, MMP-9 was induced in the tissue 
that expressed only MMP-2 in the normal situation. It correlated with inflammatory cells 
infiltration of necrotic muscle fibers that exhibit high gelatinase intracellularly, in contrast to 
pericellular localization of gelatinase in normal muscles (Figure 3). Simultaneously, MMP-2 
expression and activation decreased within the first 24 hours and was followed by a 
progressive reconstitution of these forms afterwards. MMP-9 transcripts localized to  
 
Fig. 3. In situ zymography of normal and cardiotoxin injured muscle 3 days after injury. In 
normal muscles, gelatinase activity (shown in white) localized to the endomysium and 
mononucleated cells present at the vicinity of muscle fibers. In injured muscles, gelatinase 
activity localizes to inflammatory cells. At early time points when necrotic muscle fibers are 
invaded by inflammatory cells, gelatinase activity is detected within degenerating muscle 
fibers that are invaded by inflammatory cells. Original magnification, X40 (Alameddine, 
Unpublished results). 
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inflammatory cells and mononucleated cells at satellite cell position (Kherif et al., 1999). The 
possibility that myogenic cells upregulate MMP-9 has been confirmed recently. When 
exposed to debris of damaged myotubes, the myogenic cells upregulated MMP-9, monocyte 
chemoattractant protein (MCP)-1 and other factors necessary for angiogenesis, tissue 
regeneration, and phagocyte recruitment (Dehne et al., 2011). Latent MT1-MMP (63kDA), 
which contributes with TIMP-2 to MMP-2 activation, is processed to its active (50kDa) form 
that retained its ability to process MMP-2 and was preceded by TIMP-2 decrease (Barnes et 
al., 2009). MMP-3 and TIMP-1 transcripts were also shown to be upregulated within the first 
24 hours following cold injury. TIMP-1 started to decrease 72 hours post injury and early 
increase was followed by a decrease of active MMP-3 (Urso et al., 2010). 
4.2 Matrix Metalloproteinases in dystrophic muscles 
In dystrophic mdx and CXMD muscles, MMP-2 and MMP-9 are found in muscle extracts 
whereas only MMP-2 is found in normal muscles (Fukushima et al., 2007; Kherif et al., 1999). 
MMP-9 is upregulated in both muscles and serum of mdx mice (H. Li et al., 2009) 
throughout their lifespan (Alameddine et al., unpublished results). MT1-MMP, TIMP-1 and 
TIMP-2 are also upregulated in CXMD muscles and gelatinase activity localized to necrotic 
fibers and endomysium, demonstrated by in situ zymography (Fukushima et al., 2007). 
Differences in MMP expression and activity patterns detected in different adult mdx muscles 
- gastrocnemius, soleus and diaphragm- led Bani (Bani et al., 2008) to hypothesize that the 
microenvironment of distinct skeletal muscles may influence a particular kinetic pattern of 
MMP activity, which ultimately favors persistent inflammation and myofiber regeneration 
at different stages of the myopathy in mdx mice. Gene array analysis revealed profound 
modification of mRNA levels of several MMPs and other associated proteins in 
gastrocnemius and tibialis anterior muscles of mdx mice. MMP-3, -8, -9,-10,-12, -14 and -15 
Adamts2 and Timp-1 mRNA levels are increased, MMP-11 as well as Adamts1, Adamts5, 
Adamts8 and Timp-2 and Timp-3 were downregulated (A. Kumar et al., 2010).  
In DMD muscles, TIMP-1, TIMP-2 and MMP-2 transcripts are upregulated and MMP-2 
activity is increased (von Moers et al., 2005). TIMP-1 levels, usually increased in the serum 
and plasma of patients with fibrotic diseases, are elevated in serum, plasma, and muscle 
extracts of muscular dystrophy patients and animal models. It correlated with TGF1 levels 
in DMD and in congenital muscular dystrophy (CMD) patients but not with Becker 
muscular dystrophy patients (Sun et al., 2010). In muscle tissue from dystrophin deficient 
and LAMA2-mutated muscular dystrophy patients, pro-fibrotic TGF- is increased partly 
through a positive autocrine feedback loop and is released from decorin that is degraded by 
MMP-2. DMD fibroblasts have been shown to produce more soluble collagen, biglycan, 
decorin, TGF- and MMP-7 and less MMP-1 than normal fibroblasts. TGF- is known to 
modulate the ability of cells to synthesize various ECM components and was shown to 
modify the protein pattern produced by DMD fibroblasts upon their transformation to 
myofibroblasts. It increased MMP-7 thought to contribute to fibrosis (Fadic et al., 2006; 
Simona Zanotti et al., 2010; S. Zanotti et al., 2007).  
In Emery-Dreifuss muscular dystrophy, screening of MMP-2, MMP-9 and MT1-MMP levels 
in the serum showed an increase of MMP-2 levels in both the autosomal and X- linked 
forms, suggesting it may serve as biomarker for the detection of cardiac involvement in 
patients with no subjective cardiac symptoms (Niebroj-Dobosz et al., 2009). 
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4.3 MMPs and inflammation in the development of fibrosis 
End-stage DMD muscles are characterized by an almost complete disappearance of muscle 
fibers and their replacement by fibro-fatty tissue. Although DMD is not a fibrotic disease per se, 
their muscle biopsies are generally characterized by excessive production, deposition, and 
contraction of extracellular matrix. This accumulation results from factors, produced in 
diseased muscles, that influence the normal balance between production and/or hydrolysis of 
ECM components. Clearly, structural and functional changes of tissue microenvironment in 
dystrophic muscles are not equivalent to those that accompany normal muscle development. 
The permanent induction of wound–healing response with its inflammatory component may 
be essential contributors to the development of fibrosis in dystrophic muscles. Acute or 
chronic inflammation includes exudation of plasma proteins, recruitment of leukocytes and 
activation of cell and plasma derived inflammatory mediators as well as increased expression 
of MMPs (Manicone & McGuire, 2008). When inflammation is continuous or excessive, it is 
thought to contribute to tissue injury, organ dysfunction or chronic disease states. Inversely, 
decrease of MMP activity has been incriminated in the development of fibrotic conditions. 
Decreased MMP activity may result from dysregulation of the balance between MMPs and 
TIMPs. Upregulation of MMPs or downregulation of TIMPs activity could be applied for 
resolution of tissue fibrosis (reviewed (Hemmann et al., 2007)). 
Experimental evidence shows that inflammatory cells such as macrophages, eosinophiles 
and T lymphocytes, the major infiltrating cell types, contribute to increased fibrosis (J. 
Morrison et al., 2000). Inflammatory cells produce cytokines/chemokines that regulate 
MMPs expression. In their turn, MMPs modulate the activities of cytokines and their receptors 
at the cell surface. The list of validated ECM components, growth factors (receptors and 
binding proteins) and cytokines/chemokines substrates is compiled in table 1. 
Studies using gene microarrays have demonstrated that dystrophic muscles are 
characterized by an inflammatory “molecular signature”, in which CC chemokines are 
prominent (Y. W. Chen et al., 2000; Y. W. Chen et al., 2005; Porter et al., 2003; Porter et al., 
2002). Similarly, CC chemokines are greatly upregulated in normal skeletal muscles after 
experimental injury (Hirata et al., 2003). CC chemokine receptors (CCRs 1, 2, 3, 5) and 
ligands (macrophage inflammatory protein-1, RANTES) are expressed at higher levels in 
dystrophic than in wild-type muscles across age groups (6, 12, and 24 wk). Moreover, 
chemokine ligand expression and muscle inflammation are significantly higher in 
dystrophic diaphragms than in limb muscles of the same animals. In vitro, CCR1 is 
constitutively expressed by myotubes formed from primary myoblasts derived from 
diaphragm muscles. Stimulation of myotubes by proinflammatory cytokines (tumor 
necrosis factor-, interleukin-1, interferon-) found within the in vivo dystrophic muscle 
environment, upregulates CCR1 in mdx and wild-type myoblast cultures, and also increases 
expression of its ligand RANTES to a significantly greater degree (Demoule et al., 2005).  
In damaged muscles, various cytokines and growth factors are also released during necrosis 
and regeneration of muscle fibers. The most widely documented pro-fibrotic agent that is 
over-expressed in dystrophic muscles is TGF- It is upregulated in dystrophic muscles, 
after invasion of the damaged muscle by inflammatory cells (Y. W. Chen et al., 2005; Zhou et 
al., 2006) that were shown to express TGF-mRNA although these cells may not be the sole 
contributors to its production (Bernasconi et al., 1999; Gosselin et al., 2004). 
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Enzyme Enzymes ECM substrates Growth factors & 
Cytokines/Chemokines 
Secreted-type MMP   
Collagenases   
Interstitial collagenase 
MMP-1 
Aggrecan; Collagens I,- III, 
VII, VIII, X, XI; Entactin; Fn; 
Gelatins; Ln; Link protein; 
Tenascin; Vn; Perlecan;  
CTGF; IL1-; IGFBPs; MCP-1, 
MCP-2, MCP-3, MCP-4; TNF-
 
Neutrophil collagenase 
MMP-8 
Aggrecan; Collagens I- III; 
Gelatins; link protein 
LIX/CXCL5 
Collagenase-3 MMP-13 Aggrecan; Collagens I-III,VI, 
IX, X, XIV; Fibrillin; Fn; 
Gelatins; Osteonectin; Ln; 
Perlecan 
CTGF; MCP-3/CCL7, TGF-; 
SDF-1/CXCL12 
Collagenase-4 MMP-18 Collagen I  
Gelatinases   
Gelatinase A MMP-2 Aggrecan; Collagens I, III-V, 
VII, X- XI; Decorin; Elastin; 
Entactin; Fibrillin; Fn; 
Fibulins; Gelatins; Ln; Link 
protein; Osteonectin; 
Tenascin;  
CTGF; FGFR1; CX3CL1; IL1-; 
IGFBPs; MCP-3/CCL7; TGF-
; TNF-SDF-1/CXCL12 
Gelatinase B MMP-9 Aggrecan; Collagens III, IV-V, 
XI; Decorin; Elastin; Entactin; 
Fibrillin; Gelatins; Ln; Link 
protein; Osteonectin; N-
telopeptide of collagen I; Vn 
MCP-3; CCL11; CCL17; 
Fractalkine; GRO-alpha; 
IGFBP-3; IL1-; IL-2R IL-
8/CXCL8; Kit-L; LIF; TGF-; 
TNF- SDF-1/CXCL12; VEGF 
Stromelysins   
Stromelysin-1 MMP-3 Aggrecan; Collagens III-V, 
VII, IX- XI; Decorin; Elastin; 
Entactin; Fibrillin; Fn; 
Gelatins;Ln; link protein; 
Osteonectin; Perlecan; 
Tenascin; Vn; 
CTGF; HB-EGF; IL1-; 
IGFBPs; MCP-1, MCP-2, 
MCP-3, MCP-4; IL-1; TGF-
; TNF-SDF-1/CXCL12; 
Stromelysin-2 MMP-10 Aggrecan; Collagens III-V; 
Elastin; Fn; Gelatin; Link 
protein  
 
Matrilysins   
Matrilysin-1 (MMP-7) Aggrecan; Collagens I, IV; 
Decorin; Elastin; Entactin; Fn; 
Fibulins; Gelatins; Ln; Link 
protein; Osteonectin; 
Osteopontin; Tenascin; Vn; 
Syndecan-1, 
CTGF; Fas-L; HB-EGF; IGFBP-
3;  
TNF-RANKL 
Matrilysin-2 MMP-26 Collagen IV; Fn; Fibrinogen; 
Gelatin; Vn 
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Furin-activated MMP   
Stromelysin-3 MMP-11 Aggrecan; Fn; Gelatins; Ln;  IGFBP-1 
Epilysin MMP-28 Unknown  
Other secreted-type MMP   
Metalloelastase MMP-12 Aggrecan; Collagen I, IV; 
Elastin; Entactin; Fibrillin; Fn; 
Gelatin; Ln; Osteonectin; Vn;  
TNF- 
RASI-1 (MMP-19) Aggrecan; Collagen I, IV; 
COMP; Fn; Gelatin; Ln; 
Tenascin;  
IGFBP-3 
Enamelysin (MMP-20) Aggrecan; Amelogenin; 
COMP; Gelatin;  
Unknown 
MMP-21 Unknown Unknown 
MMP-27 Unknown Unknown 
Membrane-anchored 
MMP 
  
Type I transmembrane-
type MMP 
  
MT1-MMP MMP-14 Aggrecan; Collagens I-III, VI; 
Entactin; Fibrillin; Fn; 
Gelatins; Ln; Osteonectin; Vn;  
CTGF; IL-8; MCP-3/CCL7; 
TNF- 
MT2-MMP MMP-15 Aggrecan; Entactin   
MT3-MMP MMP-16 Collagen III; Fn; Gelatins  
MT5-MMP MMP-24 PG  
GPI-linked MMP   
MT4-MMP MMP-17 Gelatin;   
MT6-MMP MMP-25 collagen IV; Fibrin; Fn; 
Gelatin; Ln 
 
Type II transmembrane-
type MMP 
Gelatins  
MMP-23   
CCL11, CC chemokine ligand 11; CCL17, CC chemokine ligand 17, COMP, cartilage oligomeric matrix 
protein; CTGF, connective tissue growth factor; Fas-L, Fas ligand; FGF, Fibroblast Growth Factor;, FGFR1, 
Fibroblast growth factor receptor 1; Fn, fibronectin; HB-EGF, heparin-binding epidermal growth factor like 
growth factor; IGFBP, insulin-like growth factor binding proteins; IL1-, interleukin-1; IL-2RInterleukin 
2 receptorL-8, interleukin 8; Kit-L, kit ligand; Ln, laminin; LIF, Leukimia inhibitory factor; LIX-CXL, 
lipopolysaccharide induced CXC chemokine, MCP-, monocyte chemotactic protein-; PCPE, Procollagen C 
protein enhancer; PG, proteoglycan; Pro, proteinase type; SDF-1/CXCL12, Stromal cell derived factor, 
TNF-, tumor necrosis factor-; TGF- transforming growth factor RASI-1, rheumatoid arthritis 
synovium inflamed-1; RANKL, receptor activator for nuclear factor  B ligand.  
Table 1. Validated MMPs substrates that include ECM and non-ECM proteins. Of the long 
list of non-ECM substrates, only growth factors, receptors and cytokines/chemokines have 
been extracted because of the role they play in the modification of tissue environment and 
the modulation of cell functions (Manicone & McGuire, 2008; C. J. Morrison et al., 2009; 
Shiomi et al., 2010; Sternlicht & Werb, 2001).  
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TGF- is thought to play a prominent role in the pathogenesis of muscle fibrosis. Its short-
term neutralization by decorin administration resulted in a 40% decline in type I collagen 
mRNA expression in mdx mice. In vitro, it stimulates collagen synthesis and inhibits collagen 
degradation in fibroblasts (Grande et al., 1997; Ignotz & Massague, 1986; Sharma & Ziyadeh, 
1994)}. Myoblast stimulation by TGF-1 induced autocrine production of TGF-1, 
downregulation of myogenic proteins, production of fibrosis-related proteins and 
phenotypic transformation of myogenic cells to fibrobroblast/myofibroblast cell types in 
vitro (Yong Li et al., 2004). TGF-treatment of myogenic cells also upregulated Connective 
Tissue Growth Factor (CTGF) (Maeda et al., 2005) incriminated in various fibrotic diseases. 
CTGF is overexpressed in dystrophic muscles and is thought to contribute, with TGF-, to  
the development of fibrosis (Sun et al., 2008)Interestingly, both factors are validated MMPs 
substrates and could be modulated through MMPs action.  
Tumor necrosis factor-(TNF-), also upregulated in muscular dystrophy (Porreca et al., 
1999) may exert direct adverse effects on skeletal muscle function and regeneration 
potential. Blockade of TNF-by inhibitory antibodies reduced necrosis and contractile 
dysfunction in response to eccentric exercise (Piers et al., 2011; Radley et al., 2008). In vitro 
TNF- has been shown to stimulate collagen synthesis in fibroblasts (Lurton et al., 1999) 
hence contributing directly to muscle fibrosis. In vivo, short-term pharmacological blockade 
of TNF- in mdx mice significantly reduced the level of both TGF-1 and type I collagen 
mRNA (Gosselin et al., 2004). Whether TNF- mediates muscle fibrosis directly or indirectly 
(by upregulating the expression of TGF-1) remains an open question. However, TNF- 
induces MMP-9 upregulation in myogenic cells (Torrente et al., 2003). 
Concomitance between inflammation and upregulation of MMPs in mouse models or 
human diseases with inflammatory conditions, led several groups to propose MMPs as 
potential therapeutic targets in pathological conditions with aberrant MMP expression and 
activity (reviewed (Clutterbuck et al., 2009)). Inhibition of MMPs has been recently 
investigated in mdx mice. MMP-9 inhibition either by the administration of nuclear factor-
kappa B inhibitory peptide, gene deletion or by L-arginine treatment was reported to reduce 
muscle injury, inflammation, fibrosis and decrease pro-inflammatory cytokine release (Hnia 
et al., 2008; A. Kumar et al., 2010; H. Li et al., 2009). However, whether this inhibition is 
acting directly on the development of fibrosis or through prevention of muscle fibers 
necrosis and tissue scarring remains an open question.  
Extreme precaution has to be taken into consideration regarding MMPs inhibition in muscular 
dystrophy particularly as animal models of MMP gain- or loss- of function and clinical trials of 
MMP inhibition in cancer patients have unraveled the dual role an individual MMP could 
exert, depending on tissue type or stage of the disease (protective/detrimental) (reviewed 
(Fanjul-Fernandez et al., 2010). In skeletal muscles, the beneficial effect of certain MMPs has 
been documented, underscoring the necessity for better knowledge of the role MMPs are 
playing in muscle diseases (Alameddine manuscript in preparation). Indeed, Mmp-2 gene 
ablation has been shown to impair the growth of muscle fibers by downregulating VEGF and 
nNOS (Miyazaki et al., 2011). Moreover, proteinases upregulation, during satellite cells 
activation, is essential for dismantling the satellite cells niche (Pallafacchina et al., 2010) and 
MMP-1 has been shown to reduce muscle fibrosis (Kaar et al., 2008).  
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4.4 MMPs favor cell migration  
Myogenic cells have been reported to express various MMPs -MMP-1, -2, -3, -7, -9, -10, -14 
and -16, either constitutively or after treatment with growth factors, cytokines or phorbol 
esters (Balcerzak et al., 2001; Caron et al., 1999; El Fahime et al., 2000; Guérin & Holland, 
1995; Kherif et al., 1999; Lewis et al., 2000; Lluri & Jaworski, 2005; Nishimura et al., 2008; 
Ohtake et al., 2006). Cytokines and growth factors differentially modulate MMPs expression 
in myogenic cells. Treatment of adult mouse myoblasts by soluble serum fibronectin, PDGF-
BB, TGF- or IGF-1 had no effect on the expression of MMP-9 expression, whereas TNF- 
and b-FGF reproducibly induced the expression of MMP-9 expression 30- and 10-folds. 
Other MMPs, such as MMP-1 and MMP-2, were not significantly affected by any of these 
growth factors (Allen et al., 2003; Torrente et al., 2003). 
 
Fig. 4. Invasion assay establishing the correlation between migratory capacity of myogenic 
cells and MMP-9 expression levels. Three different cell types, C2C12 and 2 variant clones, 
expressing different levels of MMP-2 and MMP-9, that were quantified in the same 
zymography gels with Image J, were assayed in a two chamber migration assay with (+Mat) 
or without (–Mat) growth factor reduced Matrigel as substrate. The invasive capacity is 
measured by the ratio between cells that migrated through Matrigel and those diffused 
through the porous membrane. MMP-2, MMP-9 and total gelatinase values are expressed in 
arbitrary units. Invasive capacity of C2M9 was > to C2C12>C2F cells.  
The role MMPs/TIMPs play in myogenic cells migration and potentially in cell fusion has 
been confirmed by overexpression and inhibition studies. Myoblasts overexpressing MMP-7 
had a higher propensity to form myotubes than parental controls and generated more fibers 
when transplanted into a single site (Caron et al., 1999). MMP-1 enhanced C2C12 myoblast 
migration in a wound healing assay in vitro by increasing the expression of migration related 
marker proteins such as N-cadherin, -catenin, latent MMP-2 and TIMP-1 (Wang et al., 2009). 
C2C12 cells stably transfected with MMP-2 and MMP-14 cDNA significantly increased the 
number of myonuclei without affecting the number of myotubes formed (Echizenya et al., 
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2005). MT1-MMP has been proposed as a major MMP checkpoint regulator of myotube 
formation, as shMT1-MMP partly inhibited muscle cell fusion at a specific stage (Ohtake et al., 
2006). MMP-9 and TIMP-1 have also been suspected to play a role in myogenesis in vitro. 
MMP-9 expression in human myogenic cells favored their migration on fibronectin and its 
inhibition by a blocking antibody decreased two dimensional cell migration (Lewis et al., 
2000). Cells overexpressing MMP-9 have also better three dimensional migratory capacities 
(Figure 4). They exhibit higher migration when seeded on top of a Matrigel gel that better 
mimics ECM and their migration is inhibited in the presence of a specific MMP-9 inhibitor 
(Morgan et al., 2010). Of relevance to this review is that these cells have also higher 
engraftment capacities. Upon transplantation in a single site in irradiated and non-irradiated 
muscles of mdx nu/nu mice, they formed more dystrophin positive muscle fibers over larger 
areas, indicating they migrated better in a dystrophic environment (Morgan et al., 2010).  
5. Conclusion 
Although promising, there are several challenges to be overcome before stem or precursor 
cells could be used to treat muscular dystrophies. Apart from reliably and reproducibly 
identifying and purifying the cells of interest, their characteristics have to be maintained on 
expansion in culture: attempts at re-creating the niche in vitro may facilitate the retention of 
stem cell characteristics (Cosgrove et al., 2009; Gilbert et al., 2010). Encouraging results from 
one laboratory should be independently confirmed, before any particular stem cell is 
considered for therapeutic application.  
Systemic delivery would involve turning a cell into a leukocyte to cross the blood vessel 
endothelium (Springer, 1994) and then switching on survival, migration, proliferative and 
myogenic regulatory factors once the cells are within the muscle. Even if it does not prove 
possible to treat muscles body-wide, transplanting stem cells locally into a small, vital, 
muscle, e.g. in the finger, may prove more practicable and although not life-saving, would 
improve the quality of life of DMD patients. 
But for successful local as well as systemic delivery of stem cells to skeletal muscle, the 
inhospitable muscle environment remains a major hurdle. Studies on the factors and signaling 
pathways that hinder donor cell survival, proliferation and migration within both normal and 
dystrophic muscle and how these may be modified to augment the regenerative capacity of 
transplanted cells, remain vital for the successful use of stem cells in neuromuscular diseases. 
More importantly, elucidation of the role MMPs in general and individual MMPs in particular, 
play in the modulation of the dystrophic microenvironment and stem cell response to this 
environment warrants further study. In light of our present knowledge, it is tempting to 
propose that MMPs are temporally upregulated to permit migration and fusion of stem cells, 
then down-regulated, after donor-derived muscle has been formed, to reduce inflammation 
and fibrosis and thus improve muscle function. However, it is not clear whether the presence 
of either stem cells of normal origin, or muscle fibers expressing dystrophin, are sufficient to 
prevent the uncontrolled wound healing response that occurs in dystrophic muscles. 
6. Acknowledgments 
J.E.M is funded by a Wellcome Trust University award, the Muscular Dystrophy Campaign, 
the Duchenne Parent Project (Netherlands), the International Collaborative Effort for 
www.intechopen.com
 
Muscular Dystrophy 
 
428 
Duchenne muscular dystrophy, and the Medical Research Council. H.S.A is funded by 
Association Institut de Myologie/Association Française contre les Myopathies and by 
INSERM (France). 
7. References 
Alameddine, H.S.; Dehaupas, M. & Fardeau, M. (1989). Regeneration of skeletal muscle 
fibers from autologous satellite cells multiplied in vitro. An experimental model for 
testing cultured cell myogenicity. Muscle Nerve, Vol.12, No.7, (Jul), pp. 544-55, ISSN 
0148-639X  
Alameddine, H.S.; Hantaï D.; Dehaupas, M.; & Fardeau, M. (1991). Role of persisting 
basement membrane in the reorganization of myofibres originating from myogenic 
cell grafts in the rat. Neuromuscular Disorders, Vol.1, No.2, pp. 143-52, ISSN 0960-
8966  
Alameddine, H.S.; Louboutin,J.P.; Dehaupas, M.; Sebille,A. & Fardeau, M. (1994). Functional 
recovery induced by satellite cell grafts in irreversibly injured muscles. Cell 
Transplantation, Vol.3, No.1, (Jan-Feb), pp. 3-14, ISSN 0963-6897  
Allen, D.L.; Teitelbaum, D.H. & Kurachi, K. (2003). Growth factor stimulation of matrix 
metalloproteinase expression and myoblast migration and invasion in vitro. 
American Journal of Physiology - Cell Physiology, Vol.284, No.4, (Apr 1), pp. C805-
C815,  
Arechavala-Gomeza, V.; Kinali, M.; Feng, L.; Guglieri, M.; Edge, G.; Main, M.; Hunt, D.; 
Lehovsky, J.; Straub, V.; Bushby, K.; Sewry, C.A.; Morgan, J.E. & Muntoni, F. (2010). 
Revertant fibres and dystrophin traces in Duchenne muscular dystrophy: 
implication for clinical trials. Neuromuscular Disorders, Vol.20, No.5, (May), pp. 295-
301, ISSN 1873-2364  
Balcerzak, D.; Querengesser, L.; Dixon, W.T. & Baracos, V.E. (2001). Coordinated expression 
of matrix-degrading proteinases and their activators and inhibitors in bovine 
skeletal muscle. Journal Animal Sciences, Vol.79, No.1, (Jan 1), pp. 94-107,  
Bani, C.; Lagrota-Candido, J.; Pinheiro, D.F.; Leite, P.E.; Salimena, M.C.; Henriques-Pons, A. 
& Quirico-Santos, T. (2008). Pattern of metalloprotease activity and myofiber 
regeneration in skeletal muscles of mdx mice. Muscle Nerve, Vol.37, No.5, (May), 
pp. 583-92, ISSN 0148-639X  
Banks, G.B. & Chamberlain, J.S. (2008). The value of mammalian models for Duchenne 
muscular dystrophy in developing therapeutic strategies. Current Topics in 
Developmental Biology, Vol.84, pp. 431-53,  
Barnes, B.R.; Szelenyi,E.R.; Warren, G.L. & Urso, M.L. (2009). Alterations in mRNA and 
protein levels of metalloproteinases-2, -9, and -14 and tissue inhibitor of 
metalloproteinase-2 responses to traumatic skeletal muscle injury. American Journal 
of Physiology – Cell Physiology, Vol.297, No.6, (Dec), pp. C1501-8, ISSN 1522-1563  
Beauchamp, J.R.; Morgan, J.E.; Pagel, C.N. & Partridge, T.A. (1999). Dynamics of myoblast 
transplantation reveal a discrete minority of precursors with stem cell-like 
properties as the myogenic source. The Journal of Cell Biology, Vol.144, No.6, (Mar 
22), pp. 1113-22,  
Bekaert, S.; De Meyer, T. & Van Oostveldt, P. (2005). Telomere attrition as ageing biomarker. 
Anticancer Research, Vol.25, No.4, (Jul-Aug), pp. 3011-21, ISSN 0250-7005  
www.intechopen.com
Stem Cell Based Therapy for Muscular Dystrophies:  
Cell Types and Environmental Factors Influencing Their Efficacy 
 
429 
Benchaouir, R.; Meregalli, M.; Farini ,A.; D'Antona, G.; Belicchi, M.; Goyenvalle, A.; 
Battistelli, M.; Bresolin, N.; Bottinelli, R.; Garcia, L. & Torrente, Y. (2007). 
Restoration of human dystrophin following transplantation of exon-skipping-
engineered DMD patient stem cells into dystrophic mice. Cell Stem Cell, Vol.1, No.6, 
(Dec 13), pp. 646-57,  
Bernasconi, P.; Di Blasi, C.; Mora, M.; Morandi, L.; Galbiati, S.; Confalonieri, P.; Cornelio, 
F.& Mantegazza, R. (1999). Transforming growth factor-[beta]1 and fibrosis in 
congenital muscular dystrophies. Neuromuscular Disorders, Vol.9, No.1, (Jan 1), pp. 
28-33,  
Berthon, P.; Duguez, S.; Favier, F.B.; Amirouche, A.; Feasson, L.; Vico, L.; Denis, C. & 
Freyssenet, D. (2007). Regulation of ubiquitin-proteasome system, caspase enzyme 
activities, and extracellular proteinases in rat soleus muscle in response to 
unloading. Pflügers Archives, Vol.454, No.4, (Jul), pp. 625-33, ISSN 0031-6768  
Blau, H.M.; Webster, C. & Pavlath, G.K. (1983). Defective myoblasts identified in Duchenne 
muscular dystrophy. Proceedings of the National Academy of Science USA, Vol.80, 
No.15, (Aug), pp. 4856-60, ISSN 0027-8424  
Blaveri, K.; Heslop, L.; Yu, D.S.; Rosenblatt, J.D.; Gross, J.G.; Partridge, T.A. & Morgan, J.E. 
(1999). Patterns of repair of dystrophic mouse muscle: studies on isolated fibers. 
Developmental Dynamics, Vol.216, No.3, pp. 244-56., ISSN  
Bockhold, K.J.; Rosenblatt J.D. & Partridge, T.A. (1998). Aging normal and dystrophic mouse 
muscle: analysis of myogenicity in cultures of living single fibers. Muscle Nerve, 
Vol.21, No.2, (Feb), pp. 173-83,  
Bokhoven, M.; Stephen, S.L.; Knight, S.; Gevers, E.F.; Robinson, I.C.; Takeuchi, Y. & Collins, 
M.K. (2009). Insertional gene activation by lentiviral and gammaretroviral vectors. 
Journal of Virology, Vol.83, No.1, (Jan), pp. 283-94,  
Boldrin, L.; Muntoni, F. & Morgan, J.E. (2010). Are human and mouse satellite cells really the 
same? Journal of Histochemistry &  Cytochemistry, Vol.58, No.11, (Nov), pp. 941-55, 
ISSN 1551-5044  
Boldrin, L.; Zammit, P.S.; Muntoni, F. & Morgan, J.E. (2009). Mature adult dystrophic mouse 
muscle environment does not impede efficient engrafted satellite cell regeneration 
and self-renewal. Stem Cells, Vol.27, No.10, pp. 2478-2487, ISSN 1549-4918 
Bourboulia, D. & Stetler-Stevenson, W.G. (2010). Matrix metalloproteinases (MMPs) and 
tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in 
tumor cell adhesion. Seminars in Cancer Biology, Vol.15, No.11, (Nov), pp. 1109-24,  
Brimah, K.; Ehrhardt, J.; Mouly, V.; Butler-Browne, G.S.; Partridge, T.A. & Morgan, J.E. 
(2004). Human muscle precursor cell regeneration in the mouse host is enhanced by 
growth factors. Human Gene Therapy, Vol.15, No.11, (Nov), pp. 1109-24,  
Bulfield, G.; Siller, W.G.; Wight, P.A. & Moore, K.J. (1984). X chromosome-linked muscular 
dystrophy (mdx) in the mouse. Proceedings of the National Academy of Science 
USA,Vol.81, No.4, (Feb), pp. 1189-92,  
Bushby, K.; Finkel, R.; Birnkrant, D.J.; Case, L.E.; Clemens, P.R.; Cripe, L.; Kaul, A.; Kinnett, 
K.; McDonald, C.; Pandya, S.; Poysky, J.; Shapiro, F.; Tomezsko, J. & Constantin, C. 
(2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: 
diagnosis, and pharmacological and psychosocial management. Lancet Neurology, 
Vol.9, No.1, (Jan), pp. 77-93, ISSN 1474-4465  
www.intechopen.com
 
Muscular Dystrophy 
 
430 
Caron, N.J.; Asselin, I.; Morel, G. & Tremblay, J.P. (1999). Increased myogenic potential and 
fusion of matrilysin-expressing myoblasts transplanted in mice. Cell 
Transplantation, Vol.8, No.5, (Sep-Oct), pp. 465-76, ISSN 0963-6897  
Chan, J.; O'Donoghue, K.; Gavina, M.; Torrente, Y.; Kennea, N.; Mehmet, H.; Stewart, H.; 
Watt ,D.J.; Morgan, J.E. & Fisk, N.M. (2006). Galectin-1 induces skeletal muscle 
differentiation in human fetal mesenchymal stem cells and increases muscle 
regeneration. Stem Cells, Vol.24, No.8, (Aug), pp. 1879-91,  
Chen, Y.W.; Zhao, P.; Borup, R. & Hoffman, E. (2000). Expression profiling in the muscular 
dystrophies: identification of novel aspects of molecular pathophysiology. The 
Journal of Cell Biology, Vol.151, pp. 1321–36,  
Chen, Y.W.; Nagaraju, K.; Bakay, M.; McIntyre, O.; Rawat, R.; Shi, R. & Hoffman, E.P. (2005). 
Early onset of inflammation and later involvement of TGF{beta} in Duchenne 
muscular dystrophy. Neurology, Vol.65, No.6, (Sep 27), pp. 826-834,  
Ciuffi, A. (2008). Mechanisms governing lentivirus integration site selection. Current Gene 
Therapy, Vol.8, No.6, (Dec), pp. 419-29,  
Clutterbuck, A.L.; Asplin, K.E.; Harris, P.; Allaway, D. & Mobasheri, A. (2009). Targeting 
matrix metalloproteinases in inflammatory conditions. Current Drug Targets, Vol.10, 
No.12, (Dec), pp. 1245-54, ISSN 1873-5592  
Collins, C.A. & Morgan, J.E. (2003). Duchenne's muscular dystrophy: animal models used to 
investigate pathogenesis and develop therapeutic strategies. International Journal of 
Experimental Pathology, Vol.84, No.4, (Aug), pp. 165-72,  
Collins, C.A.; Olsen, I.; Zammit, P.S.; Heslop, L.; Petrie, A.; Partridge T.A. & Morgan,. J.E. 
(2005). Stem cell function, self-renewal, and behavioral heterogeneity of cells from 
the adult muscle satellite cell niche. Cell, Vol.122, No.2, pp. 289-301,  
Cooper, R.N.; Irintchev, A.; Di Santo, J.P.; Zweyer, M.; Morgan, J.E.; Partridge, T.A.; Butler-
Browne, G.S.; Mouly, V. & Wernig, A. (2001). A new immunodeficient mouse 
model for human myoblast transplantation. Human Gene Therapy, Vol.12, No.7, 
(May 1), pp. 823-31,  
Cosgrove, B.D.; Sacco, A.; Gilbert, P.M. & Blau, H.M. (2009). A home away from home: 
challenges and opportunities in engineering in vitro muscle satellite cell niches. 
Differentiation, Vol.78, No.2-3, (Sep-Oct), pp. 185-94, ISSN 1432-0436  
Cousins, J.C.; Woodward, K.J.; Gross, J.G.; Partridge, T.A. & Morgan, J.E. (2004). 
Regeneration of skeletal muscle from transplanted immortalised myoblasts is 
oligoclonal. Journal of Cell Science, Vol.117, No.15, (Jul 1), pp. 3259-3269,  
Decary, S.; Mouly, V. & Butler-Browne, G.S. (1996). Telomere length as a tool to monitor 
satellite cell amplification for cell-mediated gene therapy. Human Gene Therapy, 
Vol.7, No.11, (Jul 10), pp. 1347-50,  
Decary, S.; Mouly, V.; Hamida, C.B.; Sautet, A.; Barbet, J.P. & Butler-Browne, G.S. (1997). 
Replicative potential and telomere length in human skeletal muscle: implications 
for satellite cell-mediated gene therapy. Human Gene Therapy, Vol.8, No.12, (Aug 
10), pp. 1429-38,  
Dehne, N.; Kerkweg, U.; Flohe, S.B.; Brune, B. & Fandrey, J. (2011). Activation of HIF-1 in 
skeletal muscle cells after exposure to damaged muscle cell debris. Shock, Vol. 35, 
No.6, (Jun), pp. 632-8., ISSN 1073-2322 
Dellavalle, A.; Sampaolesi, M.; Tonlorenzi, R.; Tagliafico, E.; Sacchetti, B.; Perani, L.; 
Innocenzi, A.; Galvez, B.G.; Messina, G.; Morosetti, R.; Li, S.; Belicchi, M.; Peretti, 
www.intechopen.com
Stem Cell Based Therapy for Muscular Dystrophies:  
Cell Types and Environmental Factors Influencing Their Efficacy 
 
431 
G.; Chamberlain, J.S.; Wright, W.E.; Torrente, Y.; Ferrari, S.; Bianco P. & Cossu, G. 
(2007). Pericytes of human skeletal muscle are myogenic precursors distinct from 
satellite cells. Nature Cell Biology, Vol.9, No.3, (Mar), pp. 255-67,  
Demoule, A.; Divangahi, M.; Danialou, G.; Gvozdic, D.; Larkin, G.; Bao; W.& Petrof, B.J. 
(2005). Expression and regulation of CC class chemokines in the dystrophic (mdx) 
diaphragm. American Journal of Respiratory Cell and Molecular Biology, Vol.33, No.2, 
(Aug), pp. 178-185,  
Diaz-Manera, J.; Touvier, T.; Dellavalle, A.; Tonlorenzi, R.; Tedesco, F.S.; Messina, G.; 
Meregalli, M.; Navarro, C.; Perani, L.; Bonfanti, C.; Illa, I.; Torrente, Y.& Cossu, G. 
(2010). Partial dysferlin reconstitution by adult murine mesoangioblasts is 
sufficient for full functional recovery in a murine model of dysferlinopathy. Cell 
death & disease, Vol.1, pp. e61, ISSN 2041-4889  
Echizenya, M.; Kondo, S.; Takahashi, R.; Oh, J.; Kawashima, S.; Kitayama, H.; Takahashi, C. 
& Noda, M. (2005). The membrane-anchored MMP-regulator RECK is a target of 
myogenic regulatory factors. Oncogene, Vol.24, No.38, pp. 5850-5857,  
Ehrhardt, J.; Brimah, K.; Adkin, C.; Partridge, T. & Morgan, J. (2007). Human muscle 
precursor cells give rise to functional satellite cells in vivo. Neuromuscular Disorders, 
Vol.17, No.8, (Aug), pp. 631-8,  
El Fahime, E.; Torrente, Y.; Caron, N.J.; Bresolin, M.D. & Tremblay, J.P. (2000). In vivo 
migration of transplanted myoblasts requires Matrix Metalloproteinase activity. 
Experimental Cell Research, Vol.258, No.2, (Aug), pp. 279-287,  
Emery, A.E. (2002). The muscular dystrophies. Lancet, Vol.359, No.9307, (Feb 23), pp. 687-95, 
ISSN 0140-6736  
Fadic, R.; Mezzano, V.; Alvarez, K.; Cabrera, D.; Holmgren, J. & Brandan, E. (2006). Increase 
in decorin and biglycan in Duchenne Muscular Dystrophy: role of fibroblasts as cell 
source of these proteoglycans in the disease. Journal of Cellular and molecular 
medicine, Vol.10, No.3, (Jul-Sep), pp. 758-69, ISSN 1582-1838  
Fanjul-Fernandez, M.; Folgueras, A.R.; Cabrera, S. & Lopez-Otin, C. (2010). Matrix 
metalloproteinases: evolution, gene regulation and functional analysis in mouse 
models. Biochimica Biophysica Acta,Vol.1803, No.1, (Jan), pp. 3-19, ISSN 0006-3002  
Ferrari, G.; Cusella-De Angelis, G.; Coletta, M.; Paolucci, E.; Stornaiuolo, A.; Cossu, G. & 
Mavilio, F. (1998). Muscle regeneration by bone marrow-derived myogenic 
progenitors. Science, Vol.279, No.5356, (Mar 6), pp. 1528-30,  
Ferre, P.J.; Liaubet, L.; Concordet, D.; SanCristobal, M.; Uro-Coste, E.; Tosser-Klopp, G.; 
Bonnet, A.; Toutain, P.L.; Hatey, F. & Lefebvre, H.P. (2007). Longitudinal analysis 
of gene expression in porcine skeletal muscle after post-injection local injury. 
Pharmaceutical Research, Vol.24, No.8, (Aug), pp. 1480-9, ISSN 0724-8741  
Frisdal, E.; Teiger, E.; Lefaucheur, J.P.; Adnot, S.; Planus, E.; Lafuma, C.& D'Ortho, M. P.. 
(2000). Increased expression of gelatinases and alteration of basement membrane in 
rat soleus muscle following femoral artery ligation. Neuropathology and Applied 
Neurobiology, Vol.26, No.1, (Feb), pp. 11-21, ISSN 0305-1846 
Fukushima, K.; Nakamura, A.; Ueda, H.; Yuasa, K.; Yoshida, K.; Takeda, S. & Ikeda, S. 
(2007). Activation and localization of matrix metalloproteinase-2 and -9 in the 
skeletal muscle of the muscular dystrophy dog (CXMDJ). BMC Musculoskeletal 
Disorders, Vol.8, pp. 54, ISSN 1471-2474  
www.intechopen.com
 
Muscular Dystrophy 
 
432 
Galvez, B.G.; Sampaolesi, M.; Brunelli, S.; Covarello, D.; Gavina, M.; Rossi, B.; Constantin, 
G.; Torrente, Y. & Cossu, G. (2006). Complete repair of dystrophic skeletal muscle 
by mesoangioblasts with enhanced migration ability. The Journal of Cell Biology, 
Vol.174, No.2, (Jul 17), pp. 231-43,  
Gerard, C.; Forest, M.A.; Beauregard, G.; Skuk, D. & Tremblay, J.P.. (2011). Fibrin gel 
improves the survival of transplanted myoblasts. Cell Transplantation, Vol.20, No.5, 
(Apr 29), pp. ISSN 1555-3892  
Giannelli, G.; De Marzo, A.; Marinosci, F. & Antonaci, S. (2005). Matrix metalloproteinase 
imbalance in muscle disuse atrophy. Histology & Histopathology, Vol.20, No.1, (Jan), 
pp. 99-106, ISSN 0213-3911 
Gilbert, P.M.; Havenstrite, K.L.; Magnusson, K.E.; Sacco, A.; Leonardi, N.A.; Kraft, P.; 
Nguyen, N.K.; Thrun, S.; Lutolf, M.P. & Blau, H.M. (2010). Substrate elasticity 
regulates skeletal muscle stem cell self-renewal in culture. Science, Vol.329, No.5995, 
(Aug 27), pp. 1078-81, ISSN 1095-9203  
Gosselin, L.E.; Williams, J.E.; Deering, M.; Brazeau, D.; Koury, S. & Martinez, D.A. (2004). 
Localization and early time course of TGF- mRNA expression in dystrophic 
muscle. Muscle Nerve, Vol.30, No.5, pp. 645-653, ISSN 1097-4598 
Goyenvalle, A. & Davies, K.E. (2011). Challenges to oligonucleotides-based therapeutics for 
Duchenne muscular dystrophy. Skeletal muscle, Vol.1, No.1, pp. 8, ISSN 2044-5040  
Grande, J.P.; Melder, D.C. & Zinsmeister, A.R. (1997). Modulation of collagen gene 
expression by cytokines: stimulatory effect of transforming growth factor-beta1, 
with divergent effects of epidermal growth factor and tumor necrosis factor-alpha 
on collagen type I and collagen type IV. Journal of Laboratory and Clinical Medicine, 
Vol.130, pp. 476–486.,  
Gross, J.G. & Morgan, J.E. (1999). Muscle precursor cells injected into irradiated mdx mouse 
muscle persist after serial injury. Muscle Nerve, Vol.22, No.2, pp. 174-85.,  
Guérin, C.W. & Holland, P.C. (1995). Synthesis and secretion of matrix-degrading 
metalloproteases by human skeletal muscle satellite cells. Developmental Dynamics, 
Vol.202, No.1, (Jan), pp. 91-99,  
Guglieri, M. & Bushby, K. (2010). Molecular treatments in Duchenne muscular dystrophy. 
Current Opinion in Pharmacology, Vol.10, No.3, (Jun), pp. 331-7, ISSN 1471-4973  
Hemmann, S.; Graf, J.; Roderfeld, M. & Roeb, E. (2007). Expression of MMPs and TIMPs in 
liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. 
Journal of Hepatology, Vol.46, No.5, pp. 955-975,  
Heslop, L.; Morgan, J.E. & Partridge, T.A. (2000). Evidence for a myogenic stem cell that is 
exhausted in dystrophic muscle. Journal of Cell Science, Vol.113 (Pt 12), (Jun), pp. 
2299-308,  
Hirata, A.; Masuda, S.; Tamura, T.; Kai, K.; Ojima, K.; Fukase, A.; Motoyoshi, K.; Kamakura, 
K.; Miyagoe-Suzuki, Y. & Takeda, S. (2003). Expression profiling of cytokines and 
related genes in regenerating skeletal muscle after cardiotoxin injection: a role for 
osteopontin. American Journal of Pathology, Vol.163, pp. 203–15,  
Hnia, K.; Gayraud, J.; Hugon, G.; Ramonatxo, M.; De La Porte, S.; Matecki, S.& Mornet, D. 
(2008). L-arginine decreases inflammation and modulates the nuclear factor-
kappaB/matrix metalloproteinase cascade in mdx muscle fibers. American Journal of 
Pathology, Vol.172, No.6, (Jun), pp. 1509-19, ISSN 1525-2191  
www.intechopen.com
Stem Cell Based Therapy for Muscular Dystrophies:  
Cell Types and Environmental Factors Influencing Their Efficacy 
 
433 
Hoffman, E.P.; Morgan, J.E.; Watkins, S.C. & Partridge, T.A. (1990). Somatic 
reversion/suppression of the mouse mdx phenotype in vivo. Journal of the 
Neurological Sciences , Vol.99, No.1, (Oct), pp. 9-25,  
Hoffman, E.P.; Bronson, A.; Levin, A.A.; Takeda, S.; Yokota, T.;. Baudy, A.R & Connor, E.M. 
(2011). Restoring dystrophin expression in duchenne muscular dystrophy muscle 
progress in exon skipping and stop codon read through. American Journal of 
Pathology, Vol.179, No.1, (Jul), pp. 12-22, ISSN 1525-2191  
Holmbeck, K.; Bianco, P.; Pidoux, I.; Inoue, S.; Billinghurst, R.C.; Wu, W.; Chrysovergis, K.; 
Yamada, S.; Birkedal-Hansen, H.& Poole, A.R. (2005). The metalloproteinase MT1-
MMP is required for normal development and maintenance of osteocyte processes 
in bone. Journal of Cell Science, Vol.118, No.Pt 1, (Jan 1), pp. 147-56, ISSN 0021-9533  
Hulboy, D.L.; Rudolph, L.A. & Matrisian, L.M. (1997). Matrix metalloproteinases as 
mediators of reproductive function. Molecular Human Reproduction, Vol.3, No.1, 
(Jan), pp. 27-45, ISSN 1360-9947  
Ignotz, R.A. & Massague, J. (1986). Transforming growth factor-beta stimulates the 
expression of fibronectin and collagen and their incorporation into the extracellular 
matrix. Journal of Biological Chemistry, Vol.261, pp. 4337–4345.,  
Irintchev, A.; Langer, M.; Zweyer, M.; Theisen R. & Wernig, A. (1997). Functional 
improvement of damaged adult mouse muscle by implantation of primary 
myoblasts. Journal of Physiology, Vol.500 (Pt 3), (May 1), pp. 775-85,  
Jackson, K.A.; Snyder, D.S. & Goodell, M.A. (2004). Skeletal muscle fiber-specific green 
autofluorescence: potential for stem cell engraftment artifacts. Stem Cells, Vol.22, 
No.2, pp. 180-7, ISSN 1066-5099  
Kaar, J.L.; Li, Y.; Blair, H.C.; Asche, G.; Koepsel, R.R.; Huard, J. & Russell, A.J. (2008). Matrix 
metalloproteinase-1 treatment of muscle fibrosis. Acta Biomaterialia, Vol.4, No.5, 
(Sep), pp. 1411-20, ISSN 1742-7061  
Kherif, S.; Lafuma, C.; Dehaupas, M.; Lachkar, S.; Fournier, J.G.; Verdiere-Sahuque, M.; 
Fardeau, M. & Alameddine, H.S. (1999). Expression of matrix metalloproteinases 2 
and 9 in regenerating skeletal muscle: a study in experimentally injured and mdx 
muscles. Developmental Biology, Vol.205, No.1, (Jan 1), pp. 158-70, ISSN 0012-1606  
Kinoshita, I.; Huard J. & Tremblay, J.P. (1994a). Utilization of myoblasts from transgenic 
mice to evaluate the efficacy of myoblast transplantation. Muscle Nerve, Vol.17, 
No.9, (Sep), pp. 975-80, ISSN 0148-639X  
Kinoshita, I.; Vilquin, J.T.; Guerette, B.; Asselin, I.; Roy, R.; Lille S. & Tremblay, J.P. (1994b). 
Immunosuppression with FK 506 insures good success of myoblast transplantation 
in mdx mice. Transplantation Proceedings, Vol.26, No.6, (Dec), pp. 3518, ISSN 0041-
1345  
Kumar, A.; Bhatnagar, S. & Kumar, A. (2010). Matrix metalloproteinase inhibitor batimastat 
alleviates pathology and improves skeletal muscle function in dystrophin-deficient 
mdx mice. American Journal of Pathology, Vol.177, No.1, (Jul), pp. 248-60, ISSN 1525-
2191  
Kumar, M.; Keller, B.; Makalou, N. & Sutton, R.E. (2001). Systematic determination of the 
packaging limit of lentiviral vectors. Human Gene Therapy, Vol.12, No.15, (Oct 10), 
pp. 1893-905,  
Lai, Y.; Thomas, G.D.; Yue, Y.; Yang, H.T.; Li, D.; Long, C.; Judge, L.; Bostick, B.; 
Chamberlain, J.S.; Terjung, R.L. & Duan, D. (2009). Dystrophins carrying spectrin-
www.intechopen.com
 
Muscular Dystrophy 
 
434 
like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise 
performance in a mouse model of muscular dystrophy. The Journal of Clinical 
Investigation, Vol.119, No.3, (Mar), pp. 624-35,  
Lefaucheur, J.P. & Sebille, A. (1995). Basic fibroblast growth factor promotes in vivo muscle 
regeneration in murine muscular dystrophy. Neuroscience Letters, Vol.202, No.1-2, 
(Dec 29), pp. 121-4,  
Lewis, M.P.; Tippett, H.L.; Sinanan, A.C.; Morgan, M.J. & Hunt, N.P. (2000). Gelatinase-B 
(matrix metalloproteinase-9; MMP-9) secretion is involved in the migratory phase 
of human and murine muscle cell cultures. Journal of Muscle Research and Cell 
Motility, Vol.21, No.3, pp. 223-233,  
Li, H.; Mittal, A.; Makonchuk, D.Y.; Bhatnagar, S. & Kumar, A. (2009). Matrix 
metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal 
muscle regeneration in muscular dystrophy. Human Molecular Genetics, Vol.18, 
No.14, (Jul 15), pp. 2584-98, ISSN 1460-2083  
Li, S.; Kimura, E.; Fall, B.M.; Reyes, M.; Angello, J.C.; Welikson, R.; Hauschka, S.D. & 
Chamberlain, J.S. (2005). Stable transduction of myogenic cells with lentiviral 
vectors expressing a minidystrophin. Gene Therapy , Vol.12, No.14, (Jul), pp. 1099-
108,  
Li, Y.; Foster, W.; Deasy, B.M.; Chan, Y.; Prisk, V.; Tang ,Y.; Cummins, J. & Huard, J. (2004). 
Transforming Growth Factor-{beta}1 induces the differentiation of myogenic cells 
into fibrotic cells in injured skeletal muscle: A key event in muscle fibrogenesis. 
American Journal of Pathology, Vol.164, No.3, (March 1, 2004), pp. 1007-1019,  
Liu, X.; Lee, D.J.; Skittone, L.K.; Natsuhara, K. & Kim, H.T. (2010). Role of gelatinases in 
disuse-induced skeletal muscle atrophy. Muscle Nerve, Vol.41, No.2, (Feb), pp. 174-
8, ISSN 1097-4598  
Lluri, G. & Jaworski, D.M. (2005). Regulation of TIMP-2, MT1-MMP, and MMP-2 expression 
during C2C12 differentiation. Muscle Nerve, Vol.32, No.4, (Oct), pp. 492-9, ISSN 
0148-639X  
Lurton, J.; Soto, H.; Narayanan, A. & Raghu, G. (1999). Regulation of human lung fibroblast 
C1q-receptors by transforming growth factor-beta and tumor necrosis factor-alpha. 
Experimental Lung Research, Vol.25, pp. 151–164,  
Maeda, N.; Kanda, F.; Okuda, S.; Ishihara, H. & Chihara, K. (2005). Transforming growth 
factor-beta enhances connective tissue growth factor expression in L6 rat skeletal 
myotubes. Neuromuscular Disorders, Vol.15, No.11, (Nov), pp. 790-3,  
Manicone, A.M. & McGuire, J.K. (2008). Matrix metalloproteinases as modulators of 
inflammation. Seminars of Cell and Developmental Biology, Vol.19, No.1, (Feb), pp. 34-
41, ISSN 1084-9521  
Mather, K.A.; Jorm, A.F.; Parslow, R.A. & Christensen, H. (2011). Is telomere length a 
biomarker of aging? A review. The Journals of Gerontology. Series A, Biological sciences 
and medical sciences, Vol.66, No.2, (Feb), pp. 202-13, ISSN 1758-535X  
Mauro, A. (1961). Satellite cell of skeletal muscle fibers. Journal of Biophysical and Biochemical 
Cytology, Vol.9, (Feb), pp. 493-5, ISSN 0095-9901  
Meng, J.; Muntoni, F.& Morgan, J.E. (2011a). Stem cells to treat muscular dystrophies - 
where are we? Neuromuscular Disorders, Vol.21, No.1, (Jan), pp. 4-12, ISSN 1873-
2364  
www.intechopen.com
Stem Cell Based Therapy for Muscular Dystrophies:  
Cell Types and Environmental Factors Influencing Their Efficacy 
 
435 
Meng, J.; Adkin, C.F.; Xu, S.W.; Muntoni, F. & Morgan, J.E. (2011b). Contribution of human 
muscle-derived cells to skeletal muscle regeneration in dystrophic host mice. PloS 
One, Vol.6, No.3, pp. e17454, ISSN 1932-6203  
Meng, J.; Adkin, C.F.; Arechavala-Gomeza, V.; Boldrin, L.; Muntoni, F. & Morgan, J.E. 
(2010). The contribution of human synovial stem cells to skeletal muscle 
regeneration. Neuromuscular Disorders, Vol.20, No.1, (Jan), pp. 6-15, ISSN 1873-2364  
Meregalli, M.; Farini, A. & Torrente, Y. (2008). Combining stem cells and exon skipping 
strategy to treat muscular dystrophy. Expert Opinion in Biological Therapy, Vol.8, 
No.8, (Aug), pp. 1051-61,  
Miyazaki, D.; Nakamura, A.; Fukushima, K.; Yoshida, K.; Takeda, S. & Ikeda, S.I. (2011). 
Matrix metalloproteinase-2 ablation in dystrophin-deficient mdx muscles reduces 
angiogenesis resulting in impaired growth of regenerated muscle fibers. Human 
Molecular Genetics, Vol.20, No.9, (May 1), pp. 1787-99., ISSN 1460-2083  
Monaco, A.P.; Bertelson, C.J.; Middlesworth, W.; Colletti, C.A.; Aldridge, J.; Fischbeck, K.H.; 
Bartlett, R.; Pericak-Vance, M.A.; Roses, A.D. & Kunkel, L.M. (1985). Detection of 
deletions spanning the Duchenne muscular dystrophy locus using a tightly linked 
DNA segment. Nature, Vol.316, No.6031, (Aug 29-Sep 4), pp. 842-5, ISSN 0028-0836  
Montini, E.; Cesana, D.; Schmidt, M.; Sanvito, F.; Ponzoni, M.; Bartholomae, C.; Sergi Sergi, 
L.; Benedicenti, F.; Ambrosi, A.; Di Serio, C.; Doglioni, C.; von Kalle, C. & Naldini, 
L. (2006). Hematopoietic stem cell gene transfer in a tumor-prone mouse model 
uncovers low genotoxicity of lentiviral vector integration. Nature Biotechnology, 
Vol.24, No.6, (Jun), pp. 687-96,  
Morgan, J.; Rouche, A.; Bausero, P.; Houssaini, A.; Gross, J.; Fiszman, M.Y. & 
Alameddine,H.S. (2010). MMP-9 overexpression improves myogenic cell migration 
and engraftment. Muscle Nerve, Vol.42, No.4, (Oct), pp. 584-95, ISSN 1097-4598 
Morgan, J.E. & P.S. Zammit. (2010). Direct effects of the pathogenic mutation on satellite cell 
function in muscular dystrophy. Experimental Cell Research, Vol.316, No.18, pp. 
3100-3108, ISSN 1090-2422 
Morgan, J.E.; Hoffman, E.P. & Partridge, T.A. (1990). Normal myogenic cells from newborn 
mice restore normal histology to degenerating muscles of the mdx mouse. The 
Journal of Cell Biology, Vol.111, No.6 Pt 1, pp. 2437-49.,  
Morgan, J.E.; Gross, J.G.; Pagel, C.N.; Beauchamp, J.R.; Fassati, A.; Thrasher, A.J.; Di Santo, 
J.P.; Fisher, I.B.; Shiwen, X.; Abraham, D.J.& Partridge,T.A. (2002). Myogenic cell 
proliferation and generation of a reversible tumorigenic phenotype are triggered by 
preirradiation of the recipient site. The Journal of Cell Biology, Vol.157, No.4, pp. 693-
702, ISSN 0021-9525 
Morrison, C.J.; Butler, G.S.; Rodriguez, D. & Overall, C.M. (2009). Matrix metalloproteinase 
proteomics: substrates, targets, and therapy. Current Opinion in Cell Biology, Vol.21, 
No.5, (Oct), pp. 645-53, ISSN 1879-0410 
Morrison, J.; Lu, Q.L.; Pastoret, C.; Partridge T. & Bou-Gharios, G. (2000). T-cell-dependent 
fibrosis in the mdx dystrophic mouse. Laboratory Investigation, Vol.80, No.6, pp. 881-
91.,  
Murphy, G. (2010). Fell-Muir Lecture: Metalloproteinases: from demolition squad to master 
regulators. International Journal of Experimental Pathology, Vol.91, No.4, (Aug), pp. 
303-13, ISSN 1365-2613  
www.intechopen.com
 
Muscular Dystrophy 
 
436 
Nakamura, A. & Takeda, S. (2011). Mammalian models of Duchenne Muscular Dystrophy: 
pathological characteristics and therapeutic applications. Journal of Biomedicine & 
Biotechnology,Vol.2011, pp. 184393, ISSN 1110-7251  
Negroni, E.; Vallese, D.; Vilquin, J.T.; Butler-Browne, G.; Mouly, V. & Trollet, C. (2011). 
Current advances in cell therapy strategies for muscular dystrophies. Expert 
Opinion on Biological Therapy, Vol.11, No.2, (Feb), pp. 157-76, ISSN 1744-7682  
Negroni, E.; Riederer, I.; Chaouch, S.; Belicchi, M.; Razini, P.; Di Santo, J.; Torrente, Y.; 
Butler-Browne, G.S. & Mouly, V. (2009). In vivo myogenic potential of human 
CD133+ muscle-derived stem cells: a quantitative study. Molecular Therapy, Vol.17, 
No.10, (Oct), pp. 1771-8, ISSN 1525-0024  
Niebroj-Dobosz, I.; Madej-Pilarczyk, A.; Marchel, M.; Sokolowska, B. & Hausmanowa-
Petrusewicz, I. (2009). Matrix metalloproteinases in serum of Emery-Dreifuss 
muscular dystrophy patients. Acta Biochimica Polonica, Vol.56, No.4, pp. 717-22, 
ISSN 1734-154X  
Nishimura, T.; Nakamura, K.; Kishioka, Y.; Kato-Mori, Y.; Wakamatsu, J. & Hattori, A. 
(2008). Inhibition of matrix metalloproteinases suppresses the migration of skeletal 
muscle cells. Journal of Muscle Research and Cell Motility, Vol.29, No.1, pp. 37-44, 
ISSN 0142-4319  
Ohtake, Y.; Tojo, H. & Seiki, M. (2006). Multifunctional roles of MT1-MMP in myofiber 
formation and morphostatic maintenance of skeletal muscle. Journal of Cell Science, 
Vol.119, No Pt 18, (Sep 15), pp. 3822-32, ISSN 0021-9533  
Pagel, C.N. & Partridge, T.A. (1999). Covert persistence of mdx mouse myopathy is revealed 
by acute and chronic effects of irradiation. Journal of Neurological Science, Vol.164, 
No.2, (Apr 1), pp. 103-16,  
Pallafacchina, G.; Francois, S.; Regnault, B.; Czarny, B.; Dive, V.; Cumano, A.; Montarras, D. 
& Buckingham, M. (2010). An adult tissue-specific stem cell in its niche: a gene 
profiling analysis of in vivo quiescent and activated muscle satellite cells. Stem Cell 
Research, Vol.4, No.2, (Mar), pp. 77-91, ISSN 1876-7753  
Palmieri, B.; Tremblay, J.P. & Daniele, L. (2010). Past, present and future of myoblast 
transplantation in the treatment of Duchenne muscular dystrophy. Pediatric 
transplantation, Vol.14, No.7, (Nov), pp. 813-9, ISSN 1399-3046  
Palumbo, R.; Sampaolesi, M.; De Marchis, F.; Tonlorenzi, R.; Colombetti, S.; Mondino, A.; 
Cossu G. & Bianchi, M.E. (2004). Extracellular HMGB1, a signal of tissue damage, 
induces mesoangioblast migration and proliferation. The Journal of Cell Biology, 
Vol.164, No.3, (Feb 2), pp. 441-9, ISSN 0021-9525  
Partridge, T.A.; Morgan, J.E.; Coulton, G.R.; Hoffman, E.P. & Kunkel, L.M. (1989). 
Conversion of mdx myofibers from dystrophin-negative to-positive by injection of 
normal myoblasts. Nature, Vol.337, pp. 176-179,  
Pellegrini, K.L. & Beilharz, M.W. (2011). The survival of myoblasts after intramuscular 
transplantation is improved when fewer cells are injected. Transplantation, Vol.91, 
No.5, (Mar 15), pp. 522-6, ISSN 1534-6080  
Piers, A.T.; Lavin, T.; Radley-Crabb, H.G.; Bakker, A.J.; Grounds ,M.D. & Pinniger, G.J. 
(2011). Blockade of TNF in vivo using cV1q antibody reduces contractile 
dysfunction of skeletal muscle in response to eccentric exercise in dystrophic mdx 
and normal mice. Neuromuscular Disorders, Vol.21, No.2, (Feb), pp. 132-41, ISSN 
1873-2364  
www.intechopen.com
Stem Cell Based Therapy for Muscular Dystrophies:  
Cell Types and Environmental Factors Influencing Their Efficacy 
 
437 
Pisani, D.F.; Clement, N.; Loubat, A.; Plaisant, M.; Sacconi, S.; Kurzenne, J.Y.; Desnuelle, C.; 
Dani C. &Dechesne, C.A. (2010). Hierarchization of myogenic and adipogenic 
progenitors within human skeletal muscle. Stem Cells, Vol.28, No.12, (Dec), pp. 
2182-94, ISSN 1549-4918  
Porreca, E.; Guglielmi, M.; Uncini, A.; Di Gregorio, P.; Angelini, A.; Di Febbo, C.; 
Pierdomenico, S.; Baccante G. & Cuccurullo,. F. (1999). Haemostatic abnormalities, 
cardiac involvement and serum tumor necrosis factor levels in X-linked dystrophic 
patients. Thrombosis Haemostasis, Vol.81, pp. 543–546.,  
Porter, J.D.; Guo, W.; Merriam, A.P.; Khanna, S.; Cheng, G.; Zhou, X.; Andrade, F.H.; 
Richmonds, C. & Kaminski, H.J. (2003). Persistent over-expression of specific CC 
class chemokines correlates with macrophage and T-cell recruitment in mdx 
skeletal muscle. Neuromuscular Disorders, Vol.13, pp. 223–35,  
Porter, J.D.; Khanna, S.; Kaminski, H.J.; Rao, J.S.; Merriam, A.; Richmonds, C.R.; Leahy, P.; 
Li, J.; Guo, W. & Andrade, F.H. (2002). A chronic inflammatory response dominates 
the skeletal muscle molecular signature in dystrophin-deficient mdx mice. Human 
Molecular Genetics, Vol.11, pp. 263–72,  
Praud, C.; Montarras, D.; Pinset,C. & Sebille, A. (2003). Dose effect relationship between the 
number of normal progenitor muscle cells grafted in mdx mouse skeletal striated 
muscle and the number of dystrophin-positive fibres. Neuroscience Letters, Vol.352, 
No.1, (Nov 27), pp. 70-2,  
Quenneville, S.P.; Chapdelaine, P.; Skuk, D.; Paradis, M.; Goulet, M.; Rousseau, J.; Xiao, X.; 
Garcia, L. & Tremblay, J.P. (2007). Autologous transplantation of muscle precursor 
cells modified with a lentivirus for muscular dystrophy: human cells and primate 
models. Molecular Therapy, Vol.15, No.2, (Feb), pp. 431-8,  
Radley, H.G.; Davies, M.J. & Grounds,M.D. (2008). Reduced muscle necrosis and long-term 
benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. 
Neuromuscular Disorders, Vol.18, No.3, (Mar), pp. 227-38, ISSN 0960-8966  
Rahim, A.A.; Wong, A.M.; Howe, S.J.; Buckley, S.M.; Acosta-Saltos, A.D.; Elston, K.E.; Ward, 
N.J.; Philpott, N.J.; Cooper, J.D.; Anderson, P.N.; Waddington, S.N.; Thrashe, A.J. & 
Raivich,G. (2009). Efficient gene delivery to the adult and fetal CNS using 
pseudotyped non-integrating lentiviral vectors. Gene Therapy, Vol.16, No. 4, (Apr), 
pp. 509-20, ISSN 0969-7128  
Rando, T.A. &Blau, H.M. (1994). Primary mouse myoblast purification, characterization, and 
transplantation for cell-mediated gene therapy. The Journal of Cell Biology, Vol.125, 
No.6, (Jun), pp. 1275-87, ISSN 0021-9525  
Reznick, A.Z.; Menashe, O.; Bar-Shai, M.; Coleman, R. & Carmeli, E. (2003). Expression of 
matrix metalloproteinases, inhibitor, and acid phosphatase in muscles of 
immobilized hindlimbs of rats. Muscle Nerve, Vol.27, No.1, (Jan), pp. 51-9, ISSN 
0148-639X 
Rodriguez, D.; Morrison, C.J. & Overall, C.M. (2010). Matrix metalloproteinases: what do 
they not do? New substrates and biological roles identified by murine models and 
proteomics. Biochimica Biophysica Acta, Vol.1803, No.1, (Jan), pp. 39-54, ISSN 0006-
3002  
Rosenberg, G.A. (2009). Matrix metalloproteinases and their multiple roles in 
neurodegenerative diseases. The Lancet Neurology, Vol.8, No.2, pp. 205-216,  
www.intechopen.com
 
Muscular Dystrophy 
 
438 
Sacco, A.; Doyonnas, R.; Kraft, P.; Vitorovic, S. & Blau,H.M. (2008). Self-renewal and 
expansion of single transplanted muscle stem cells. Nature, Vol.456, No.7221, (Nov 
27), pp. 502-6,  
Sacco, A.; Mourkioti, F.; Tran, R.; Choi, J.; Llewellyn, M.; Kraft, P.; Shkreli, M.; Delp, S.; 
Pomerantz, J.H.; Artandi, S.E. & Blau, H.M. (2010). Short telomeres and stem cell 
exhaustion model Duchenne muscular dystrophy in mdx/mTR mice. Cell, Vol.143, 
No.7, (Dec 23), pp. 1059-71, ISSN 1097-4172  
Sampaolesi, M.; Torrente, Y.; Innocenzi, A.; Tonlorenzi, R.; D'Antona, G.; Pellegrino, M.A.; 
Barresi, R.; Bresolin, N.; De Angelis, M.G.; Campbell, K.P.; Bottinelli, R. & Cossu, G. 
(2003). Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-
arterial delivery of mesoangioblasts. Science, Vol.301, No.5632, (Jul 25), pp. 487-92, 
ISSN 1095-9203  
Sampaolesi, M.; Blot, S.; D'Antona, G.; Granger, N.; Tonlorenzi,R.; Innocenzi, A.; Mognol, P.; 
Thibaud, J.L.; Galvez ,B.G.; Barthelemy, I.; Perani, L.; Mantero, S.; Guttinger, M.; 
Pansarasa, O.; Rinaldi, C.; Cusella De Angelis, M.G.; Torrente, Y.; Bordignon, C.; 
Bottinelli, R. & Cossu, G. (2006). Mesoangioblast stem cells ameliorate muscle 
function in dystrophic dogs. Nature, Vol.444, No.7119, (Nov 30), pp. 574-9,  
Sancricca, C.; Mirabella, M.; Gliubizzi, C.; Broccolini, A.; Gidaro, T. & Morosetti, R. (2010). 
Vessel-associated stem cells from skeletal muscle: From biology to future uses in 
cell therapy. World Journal of Stem Cells, Vol.2, No.3, (Jun 26), pp. 39-49, ISSN 1948-
0210  
Sciorati, C.; Galvez, B.G.; Brunelli, S.; Tagliafico, E.; Ferrari, S.; Cossu G.& Clementi, E. (2006). 
Ex vivo treatment with nitric oxide increases mesoangioblast therapeutic efficacy in 
muscular dystrophy. Journal of Cell Science, Vol.119,.Pt 24, (Dec 15), pp. 5114-23,  
Seale, P.;. Sabourin, L.A; Girgis-Gabardo, A.; Mansouri, A.; Gruss, P. & Rudnicki, M.A. 
(2000). Pax7 is required for the specification of myogenic satellite cells. Cell, Vol.102, 
No.6, (Sep 15), pp. 777-86,  
Sharma, K. & Ziyadeh,F.N. (1994). The emerging role of transforming growth factor-beta in 
kidney diseases. American Journal of Physiology Renal Physiology, Vol.266, pp. F829–
F842.,  
Shiomi, T.; Lemaitre, V.; D'Armiento, J. & Okada, Y. (2010). Matrix metalloproteinases, a 
disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with 
thrombospondin motifs in non-neoplastic diseases. Pathology International, Vol.60, 
No.7, (Jul), pp. 477-96, ISSN 1440-1827  
Silva-Barbosa, S.D.; Butler-Browne, G.S.; Di Santo, J.P. & Mouly, V. (2005). Comparative 
analysis of genetically engineered immunodeficient mouse strains as recipients for 
human myoblast transplantation. Cell Transplantation, Vol.14, No.7, pp. 457-67,  
Skuk, D. & Tremblay, J.P. (2011). Intramuscular cell transplantation as a potential treatment 
of myopathies: clinical and preclinical relevant data. Expert Opinion on Biological 
Therapy, Vol.11, No.3, (Mar), pp. 359-74, ISSN 1744-7682  
Skuk, D.; Roy, B.; Goulet, M. & Tremblay, J.P. (1999). Successful myoblast transplantation in 
primates depends on appropriate cell delivery and induction of regeneration in the 
host muscle. Experimental Neurology, Vol.155, No.1, (Jan), pp. 22-30, ISSN 0014-4886 
Skuk, D.; Caron, N.; Goulet, M.; Roy, B.; Espinosa, F. & Tremblay, J.P. (2002). Dynamics of 
the early immune cellular reactions after myogenic cell transplantation. Cell 
Transplantation, Vol.11, No.7, pp. 671-81,  
www.intechopen.com
Stem Cell Based Therapy for Muscular Dystrophies:  
Cell Types and Environmental Factors Influencing Their Efficacy 
 
439 
Smythe, G.M.; Fan, Y. & Grounds, M.D. (2000). Enhanced migration and fusion of donor 
myoblasts in dystrophic and normal host muscle. Muscle Nerve, Vol.23, No.4, (Apr), 
pp. 560-74, ISSN 0148-639X 
Springer, T.A. (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: 
the multistep paradigm. Cell, Vol.76, No.2, (Jan 28), pp. 301-14, ISSN 0092-8674 
Sternlicht, M.D. & Werb, Z. (2001). How matrix metalloproteinases regulate cell behavior. 
Annual Review of Cell and Developmental Biology, Vol.17, pp. 463-516, ISSN 1081-0706  
Stevenson, E.J.; Giresi, P.G.; Koncarevic, A. & Kandarian, S.C. (2003). Global analysis of gene 
expression patterns during disuse atrophy in rat skeletal muscle. Journal of 
Physiology, Vol.551, Pt 1, (Aug 15), pp. 33-48, ISSN 0022-3751  
Sugita, H. & Takeda, S. (2010). Progress in muscular dystrophy research with special 
emphasis on gene therapy. Proceedings of the Japan Academy. Series B, Physical and 
Biological sciences, Vol.86, No.7, pp. 748-56, ISSN 1349-2896 
Sun, G.; Haginoya, K.; Chiba, Y.; Uematsu, M.; Hino-Fukuyo, N.; Tanaka, S.; Onuma, A.; 
Iinuma, K. & Tsuchiya,S. (2010). Elevated plasma levels of tissue inhibitors of 
metalloproteinase-1 and their overexpression in muscle in human and mouse 
muscular dystrophy. Journal of the Neurological Sciences, Vol.297, No.1-2, pp. 19-28,  
Sun, G.; Haginoya, K.; Wu, Y.; Chiba, Y.; Nakanishi, T.; Onuma, A.; Sato, Y.; Takigawa, M.; 
Iinuma, K. & Tsuchiya, S. (2008). Connective tissue growth factor is overexpressed 
in muscles of human muscular dystrophy. Journal of Neurological Sciences, Vol.267, 
No.1, (04/15), pp. 48-56,  
Tedesco, F.S.; Dellavalle, A.; Diaz-Manera, J.; Messina G. & Cossu, G. (2010). Repairing 
skeletal muscle: regenerative potential of skeletal muscle stem cells. The Journal of 
Clinical Investigation, Vol.120, No.1, (Jan 4), pp. 11-9, ISSN 1558-8238  
Torrente, Y.; El Fahime, E.; Caron, N.J.; Del Bo, R.; Belicchi, M.; Pisati, F.; Tremblay, J.P. & 
Bresolin, N. (2003). Tumor necrosis factor-alpha (TNF-alpha) stimulates 
chemotactic response in mouse myogenic cells. Cell Transplantation, Vol.12, No.1, 
pp. 91-100, ISSN 0963-6897  
Torrente, Y.; Belicchi, M.; Sampaolesi, M.; Pisati, F.; Meregalli, M.; D'Antona, G.; Tonlorenzi, 
R.; Porretti, L.; Gavina, M.; Mamchaoui, K.; Pellegrino, M.A.; Furling, D.; Mouly, V.; 
Butler-Browne, G.S.; Bottinelli, R.; Cossu, G. & Bresolin, N. (2004). Human 
circulating AC133(+) stem cells restore dystrophin expression and ameliorate 
function in dystrophic skeletal muscle. The Journal of Clinical Investigation, Vol.114, 
No.2, (Jul), pp. 182-95,  
Urso, M.L.; Szelenyi, E.R.; Warren, G. L. & Barnes, B. R. (2010). Matrix metalloprotease-3 and 
tissue inhibitor of metalloprotease-1 mRNA and protein levels are altered in 
response to traumatic skeletal muscle injury. European Journal Applied 
Physiology,Vol.109, No.5, pp. 963-72,  
Vauchez, K.; Marolleau, J.P.; Schmid, M.; Khattar, P.; Chapel, A.; Catelain, C.; Lecourt, S.; 
Larghero, J.; Fiszman, M. & Vilquin, J.T. (2009). Aldehyde dehydrogenase activity 
identifies a population of human skeletal muscle cells with high myogenic 
capacities. Molecular Therapy, Vol.17, No.11, (Nov), pp. 1948-58, ISSN 1525-0024  
Von Moers, A.; Zwirner, A.; Reinhold, A.; Bruckmann, O.; van Landeghem, F.; Stoltenburg-
Didinger, G.; Schuppan, D.; Herbst, H. & Schuelke, M.. (2005). Increased mRNA 
expression of tissue inhibitors of metalloproteinase-1 and -2 in Duchenne muscular 
dystrophy. Acta Neuropathologica, Vol.109, No.3, (Mar), pp. 285-93, ISSN 0001-6322  
www.intechopen.com
 
Muscular Dystrophy 
 
440 
Vu, T.H. & Werb, Z. (2000). Matrix metalloproteinases: effectors of development and normal 
physiology. Genes & Development, Vol.14, No.17, (Sep 1), pp. 2123-33, ISSN 0890-
9369 
Wakeford, S.; Watt, D.J. & Partridge, T.A. (1991). X-irradiation improves mdx mouse muscle 
as a model of myofiber loss in DMD. Muscle Nerve, Vol.14, No.1, (Jan), pp. 42-50,  
Wang, W.; Pan, H.; Murray, K.; Jefferson, B.S. & Li, Y. (2009). Matrix metalloproteinase-1 
promotes muscle cell migration and differentiation. American Journal of Pathology, 
Vol.174, No.2, (Feb), pp. 541-9, ISSN 1525-2191  
Webster, C. & Blau, H.M. (1990). Accelerated age-related decline in replicative life-span of 
Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. 
Somatic Cell Molecular Genetics, Vol.16, No.6, (Nov), pp. 557-65, ISSN 0740-7750  
Wells, D.J.; Ferrer, A. & Wells, K.E. (2002). Immunological hurdles in the path to gene 
therapy for Duchenne muscular dystrophy. Expert Review Molecular Medicine,Vol.4, 
No.23, (Nov), pp. 1-23, ISSN 1462-3994  
Wilson, C.A. & Cichutek, K. (2009). The US and EU regulatory perspectives on the clinical 
use of hematopoietic stem/progenitor cells genetically modified ex vivo by 
retroviral vectors. Methods in Molecular Biology,Vol.506, pp. 477-88,  
Wittwer, M.; Flück, M.; Hoppeler, H.; Müller, S.; Desplanches D. & Billeter, R. (2002). 
Prolonged unloading of rat soleus muscle causes distinct adaptations of the gene 
profile. The FASEB Journal, Vol.16, pp. 884-886,  
Yokota, T.; Lu, Q.L.; Morgan, J.E.; Davies, K.E.; Fisher, R.; Takeda, S. & Partridge, T.A. 
(2006). Expansion of revertant fibers in dystrophic mdx muscles reflects activity of 
muscle precursor cells and serves as an index of muscle regeneration. Journal of Cell 
Science, Vol.119, Pt 13, (Jul 1), pp. 2679-87,  
Zanotti, S.; Gibertini, S.; & Mora. M. (2010). Altered production of extra-cellular matrix 
components by muscle-derived Duchenne muscular dystrophy fibroblasts before 
and after TGF-β1 treatment. Cell and Tissue Research, Vol.339, No.2, pp. 397-410,  
Zanotti, S.; Saredi, S.; Ruggieri, A.; Fabbri, M.; Blasevich, F.; Romaggi, S.; Morandi, L. & 
Mora, M. (2007). Altered extracellular matrix transcript expression and protein 
modulation in primary Duchenne muscular dystrophy myotubes. Matrix Biology, 
Vol.26, No.8, (Oct), pp. 615-24, ISSN 0945-053X  
Zhang, F.; Thornhill, S.I.; Howe, S.J.; Ulaganathan, M.; Schambach, A.; Sinclair, J.; Kinnon, 
C.; Gaspar, H.B.; Antoniou, M. & Thrasher, A.J. (2007). Lentiviral vectors 
containing an enhancer-less ubiquitously acting chromatin opening element 
(UCOE) provide highly reproducible and stable transgene expression in 
hematopoietic cells. Blood, Vol.110, No.5, (Sep 1), pp. 1448-57,  
Zheng, B.; Cao, B.; Crisan, M.; Sun, B.; Li, G.; Logar, A.; Yap, S.; Pollett, J.B.; Drowley, L.; 
Cassino, T.; Gharaibeh, B.; Deasy, B.M.; Huard, J. & Peault, B. (2007). Prospective 
identification of myogenic endothelial cells in human skeletal muscle. Nature 
Biotechnology, Vol.25, No.9, (Sep), pp. 1025-34,  
Zhou, L.; Porter, J.D.; Cheng, G.; Gong, B.; Hatala, D.A.; Merriam, A.P.; Zhou, X.; Rafael, J.A. 
& Kaminski, H.J. (2006). Temporal and spatial mRNA expression patterns of TGF-
[beta]1, 2, 3 and T[beta]RI, II, III in skeletal muscles of mdx mice. Neuromuscular 
Disorders, Vol.16, No.1, (Jan), pp. 32-38,  
www.intechopen.com
Muscular Dystrophy
Edited by Dr. Madhuri Hegde
ISBN 978-953-51-0603-6
Hard cover, 544 pages
Publisher InTech
Published online 09, May, 2012
Published in print edition May, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
With more than 30 different types and subtypes known and many more yet to be classified and characterized,
muscular dystrophy is a highly heterogeneous group of inherited neuromuscular disorders. This book provides
a comprehensive overview of the various types of muscular dystrophies, genes associated with each subtype,
disease diagnosis, management as well as available treatment options. Though each different type and
subtype of muscular dystrophy is associated with a different causative gene, the majority of them have
overlapping clinical presentations, making molecular diagnosis inevitable for both disease diagnosis as well as
patient management. This book discusses the currently available diagnostic approaches that have
revolutionized clinical research. Pathophysiology of the different muscular dystrophies, multifaceted functions
of the involved genes as well as efforts towards diagnosis and effective patient management, are also
discussed. Adding value to the book are the included reports on ongoing studies that show a promise for
future therapeutic strategies.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Jennifer Morgan and Hala Alameddine (2012). Stem Cell Based Therapy for Muscular Dystrophies: Cell Types
and Environmental Factors Influencing Their Efficacy, Muscular Dystrophy, Dr. Madhuri Hegde (Ed.), ISBN:
978-953-51-0603-6, InTech, Available from: http://www.intechopen.com/books/muscular-dystrophy/stem-cell-
based-therapy-for-muscular-dystrophies-cell-types-and-environmental-factors-influencing-th
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
